References

ometendo

Ожирение и метаболизм

Obesity and metabolism

2071-87132306-5524

Endocrinology Research Centre

10.14341/omet12714

ometendo-12714

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL PRACTICE GUIDELINES

МЕЖДИСЦИПЛИНАРНЫЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ «ЛЕЧЕНИЕ ОЖИРЕНИЯ И КОМОРБИДНЫХ ЗАБОЛЕВАНИЙ»

INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"

https://orcid.org/0000-0002-8175-7886

Дедов

И. И.

Dedov

I. I.

д.м.н., профессор, академик РАН

ResearcherID: D-3729-2014; Scopus Author ID: 7101843976; eLibrary SPIN: 5873-2280 Москва

MD, PhD, Professor, academician of RAS

ResearcherID: D-3729-2014; Scopus Author ID: 7101843976;

eLibrary SPIN: 5873-2280 Moscow

dedov@endocrincentr.ru

https://orcid.org/0000-0003-3893-9972

Шестакова

М. В.

Shestakova

M. V.

д.м.н., профессор, академик РАН

eLibrary SPIN: 7584-7015 Москва

MD, PhD, Professor, academician of RAS

eLibrary SPIN: 7584-7015 Moscow

nephro@endocrincentr.ru

https://orcid.org/0000-0002-5634-7877

Мельниченко

Г. А.

Melnichenko

G. A.

д.м.н., профессор, академик РАН

eLibrary SPIN: 8615-0038Москва

MD, PhD, Professor, academician of RAS

eLibrary SPIN: 8615-0038 Moscow

teofrast2000@mail.ru

https://orcid.org/0000-0001-8077-9381

Мазурина

Н. В.

Mazurina

N. V.

к.м.н.Москва

MD, PhD

eLibrary SPIN: 9067-3062 Moscow

natalyamazurina@mail.ru

https://orcid.org/0000-0001-8425-0020

Андреева

Е. Н.

Andreeva

E. N.

д.м.н., профессор

eLibrary SPIN: 1239-2937 Москва

MD, PhD, Professor

eLibrary SPIN: 1239-2937 Moscow

endogin@mail.ru

https://orcid.org/0000-0002-5178-6029

Бондаренко

И. З.

Bondarenko

I. Z.

д.м.н

eLibrary SPIN: 4524-4803 Москва

MD, PhD

eLibrary SPIN: 4524-4803 Moscow

iz_bondarenko@mail.ru

https://orcid.org/0000-0002-2516-2570

Гусова

З. Р.

Gusova

Z. R.

к.м.н.

eLibrary SPIN: 7295-5053

Ростов-на-Дону

MD, PhD

eLibrary SPIN: 7295-5053

Rostov-on-Don

docgzr@yandex.ru

https://orcid.org/0000-0002-0327-4619

Дзгоева

Ф. Х.

Dzgoeva

F. K.

к.м.н.

eLibrary SPIN: 9315-0722 Москва

MD, PhD

eLibrary SPIN: 9315-0722 Moscow

fatima.dzgoeva@gmail.ru

https://orcid.org/0000-0003-1191-5831

Елисеев

М. С.

Eliseev

M. S.

к.м.н.

eLibrary SPIN: 2524-7320

Москва

MD, PhD

eLibrary SPIN: 2524-7320 Moscow

elicmax@rambler.ru

https://orcid.org/0000-0002-6220-4397

Ершова

Е. В.

Ershova

E. V.

к.м.н.

eLibrary SPIN: 6728-3764 Москва

MD, PhD

eLibrary SPIN: 6728-3764 Moscow

yu99pol06@rambler.ru

https://orcid.org/0000-0002-9198-8661

Журавлева

М. В.

Zhuravleva

M. V.

д.м.н., профессор

eLibrary SPIN: 6267-9901

Москва

MD, PhD, Professor

eLibrary SPIN: 6267-9901 Moscow

mvzhuravleva@mail.ru

Захарчук

Т. А.

Zakharchuk

T. A.

к.м.н.

eLibrary SPIN: 6632-7230 Москва

MD, PhD;

eLibrary SPIN: 6632-7230 Moscow

https://orcid.org/0000-0002-4417-8076

Исаков

В. А.

Isakov

V. A.

д.м.н., профессор

eLibrary SPIN: 1182-1646 Москва

MD, PhD, Professor

eLibrary SPIN: 1182-1646 Moscow

morosoffsv@mail.ru

https://orcid.org/0000-0003-4258-1889

Клепикова

М. В.

Klepikova

M. V.

к.м.н.

eLibrary SPIN: 1718-1030

Москва

MD, PhD

eLibrary SPIN: 1718-1030 Moscow

pelageam@yandex.ru

https://orcid.org/0000-0002-6220-4397

Комшилова

К. А.

Komshilova

K. A.

к.м.н.

eLibrary SPIN: 2880-9644 Москва

MD, PhD

eLibrary SPIN: 2880-9644 Moscow

kom-ksusha@rambler.ru

https://orcid.org/0000-0002-0547-2088

Крысанова

В. С.

Krysanova

V. S.

eLibrary SPIN: 6433-2420 Москва

eLibrary SPIN: 6433-2420 Moscow

https://orcid.org/0000-0001-5981-1754

Недогода

С. В.

Nedogoda

S. V.

д.м.н., профессор

eLibrary SPIN: 7005-7846 Волгоград

MD, PhD, Professor

eLibrary SPIN: 7005-7846

Volgograd

nedogodasv@rambler.ru

https://orcid.org/0000-0002-3667-722X

Новикова

А, М.

Novikova

A. M.

eLibrary SPIN: 3821-1050

Москва

eLibrary SPIN: 3821-1050 Moscow

aleksandra.novicova@yandex.ru

https://orcid.org/0000-0002-0795-8225

Остроумова

О. Д.

Ostroumova

O. D.

к.м.н.

eLibrary SPIN: 3910-6585 Москва

MD, PhD, Professor

eLibrary SPIN: 3910-6585 Moscow

ostroumova.olga@mail.ru

https://orcid.org/0000-0001-7168-3636

Переверзев

А. П.

Pereverzev

A. P.

к.м.н.

eLibrary SPIN: 4842-3770

Москва

MD, PhD

eLibrary SPIN: 4842-3770 Moscow

acchirurg@mail.ru

https://orcid.org/0000-0002-5386-4289

Роживанов

Р. В.

Rozhivanov

R. V.

д.м.н.

eLibrary SPIN: 8052-3310 Москва

MD, PhD

eLibrary SPIN: 8052-3310 Moscow

rrozhivanov@mail.ru

https://orcid.org/0000-0003-3870-6394

Романцова

Т. И.

Romantsova

T. I.

д.м.н., профессор

eLibrary SPIN: 3855-5410 Москва

MD, PhD, Professor

eLibrary SPIN: 3855-5410 Moscow

romantsovatatiana@rambler.ru

https://orcid.org/0000-0002-6762-5238

Руяткина

Л. А.

Ruyatkina

L. A.

д.м.н., профессор

eLibrary SPIN: 1895-7664 Новосибирск

PhD, Professor

eLibrary SPIN: 1895-7664

Novosibirsk

larut@list.ru

https://orcid.org/0000-0002-6611-9165

Саласюк

А. С.

Salasyuk

A. S.

к.м.н.

eLibrary SPIN: 2651-2916 Волгоград

MD, PhD

eLibrary SPIN: 2651-2916

Volgograd

https://orcid.org/0000-0001-8896-5285

Сасунова

А. Н.

Sasunova

A. N.

eLibrary SPIN: 6237-1310 Москва

eLibrary SPIN: 6237-1310 Moscow

pilipenkowork@rambler.ru

https://orcid.org/0000-0003-3525-9891

Сметанина

С. А.

Smetanina

S. A.

д.м.н., профессор

eLibrary SPIN: 3842-6394 Тюмень

MD, PhD

eLibrary SPIN: 3842-6394

Tyumen

dr.smetanina@gmail.com

https://orcid.org/0000-0001-9262-9233

Стародубова

А. В.

Starodubova

A. V.

д.м.н., профессор

Москва

mailbox@ion.ru

https://orcid.org/0000-0001-9253-8075

Суплотова

Л. А.

Suplotova

L. A.

д.м.н., профессор

eLibrary SPIN: 1212-5397 Тюмень

MD, PhD, professor

eLibrary SPIN: 1212-5397

Tyumen

dr.suplotova@yahoo.com

https://orcid.org/0000-0002-4193-688X

Ткачева

О. Н.

Tkacheva

O. N.

д.м.н., профессор

SPIN: 6129-5809

Москва

MD, PhD, Professor

eLibrary SPIN: 6129-5809 Moscow

https://orcid.org/0000-0002-8520-8702

Трошина

Е. А.

Troshina

E. A.

д.м.н., профессор, член-корреспондент РАН

eLibrary SPIN: 8821-8990 Москва

MD, PhD, corresponding member of RAS

eLibrary SPIN: 8821-8990 Moscow

troshina@inbox.ru

https://orcid.org/0000-0003-1940-4534

Хамошина

М. Б.

Khamoshina

M. V.

д.м.н., профессор

eLibrary SPIN: 6790-4499

Москва

MD, PhD, Professor

eLibrary SPIN: 6790-4499 Moscow

https://orcid.org/0000-0003-0808-2605

Чечельницкая

С. М.

Chechelnitskaya

S. M.

д.м.н., профессор, член-корреспондент РАН

eLibrary SPIN: 8847-8731Москва

MD, PhD, Professor

eLibrary SPIN: 8847-8731

Moscow

dar-2006@bk.ru

https://orcid.org/0000-0001-6612-6851

Шестакова

Е. А.

Shestakova

E. A.

к.м.н.

eLibrary SPIN: 1124-7600 Москва

MD, PhD

eLibrary SPIN: 1124-7600

Moscow

katiashestakova@mail.ru

https://orcid.org/0000-0001-7177-0254

Шереметьева

Е. В.

Sheremet’eva

E. V.

к.м.н.

eLibrary SPIN: 9413-5136 Москва

MD, PhD

eLibrary SPIN: 9413-5136

Moscow

s1981k@yandex.ru

Национальный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation

Ростовский государственный медицинский университетРоссияRostov State Medical UniversityRussian Federation

Научно-исследовательский институт ревматологии имени В.А. НасоновойРоссияResearch Institute of Rheumatogy named after V.A. NasonovaRussian Federation

Научный центр экспертизы средств медицинского примененияРоссияScientific Centre for Expert Evaluation of Medicinal ProductsRussian Federation

Федеральный исследовательский центр питания, биотехнологии и безопасности пищиРоссияFederal Research Center of Nutrition, Biotechnology and Food SafetyRussian Federation

Российская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation

Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияSechenov First Moscow State Medical UniversityRussian Federation

Волгоградский государственный медицинский университетРоссияVolgograd State Medical UniversityRussian Federation

Российская медицинская академия непрерывного профессионального образованияРоссияA.I. Yevdokimov Moscow State University of Medicine and DentistryRussian Federation

Российская медицинская академия непрерывного профессионального образованияРоссияRussian National Research Medical University named after N.I. PirogovRussian Federation

Новосибирский государственный медицинский университетРоссияNovosibirsk State Medical UniversityRussian Federation

Тюменский государственный медицинский университетРоссияTyumen State Medical UniversityRussian Federation

Российский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияRussian National Research Medical University named after N.I. PirogovRussian Federation

Российский университет дружбы народовРоссияPeoples’ Friendship University of RussiaRussian Federation

Московский городской педагогический университетРоссияMoscow City UniversityRussian Federation

2021

11022021

181599

Copyright © Дедов И.И., Шестакова М.В., Мельниченко Г.А., Мазурина Н.В., Андреева Е.Н., Бондаренко И.З., Гусова З.Р., Дзгоева Ф.Х., Елисеев М.С., Ершова Е.В., Журавлева М.В., Захарчук Т.А., Исаков В.А., Клепикова М.В., Комшилова К.А., Крысанова В.С., Недогода С.В., Новикова А.М., Остроумова О.Д., Переверзев А.П., Роживанов Р.В., Романцова Т.И., Руяткина Л.А., Саласюк А.С., Сасунова А.Н., Сметанина С.А., Стародубова А.В., Суплотова Л.А., Ткачева О.Н., Трошина Е.А., Хамошина М.Б., Чечельницкая С.М., Шестакова Е.А., Шереметьева Е.В., 2021

2021

Дедов И.И., Шестакова М.В., Мельниченко Г.А., Мазурина Н.В., Андреева Е.Н., Бондаренко И.З., Гусова З.Р., Дзгоева Ф.Х., Елисеев М.С., Ершова Е.В., Журавлева М.В., Захарчук Т.А., Исаков В.А., Клепикова М.В., Комшилова К.А., Крысанова В.С., Недогода С.В., Новикова А.М., Остроумова О.Д., Переверзев А.П., Роживанов Р.В., Романцова Т.И., Руяткина Л.А., Саласюк А.С., Сасунова А.Н., Сметанина С.А., Стародубова А.В., Суплотова Л.А., Ткачева О.Н., Трошина Е.А., Хамошина М.Б., Чечельницкая С.М., Шестакова Е.А., Шереметьева Е.В.

Dedov I.I., Shestakova M.V., Melnichenko G.A., Mazurina N.V., Andreeva E.N., Bondarenko I.Z., Gusova Z.R., Dzgoeva F.K., Eliseev M.S., Ershova E.V., Zhuravleva M.V., Zakharchuk T.A., Isakov V.A., Klepikova M.V., Komshilova K.A., Krysanova V.S., Nedogoda S.V., Novikova A.M., Ostroumova O.D., Pereverzev A.P., Rozhivanov R.V., Romantsova T.I., Ruyatkina L.A., Salasyuk A.S., Sasunova A.N., Smetanina S.A., Starodubova A.V., Suplotova L.A., Tkacheva O.N., Troshina E.A., Khamoshina M.V., Chechelnitskaya S.M., Shestakova E.A., Sheremet’eva E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.omet-endojournals.ru/jour/article/view/12714

Клинические рекомендации уже давно вошли в число рабочих инструментов современного врача, помогая ему быстро ориентироваться в наиболее эффективных доказанных методах лечения и профилактики различных заболеваний, а также адаптировать эти методы к конкретным задачам своих больных и добиваться максимальной персонализации лечения. Клинические рекомендации составляются профессиональными некоммерческими ассоциациями и одобряются научным советом МЗ РФ, при этом нередко одна рекомендация готовится двумя или даже тремя ассоциациями. Особенность предлагаемых вашему вниманию рекомендаций в том, что в профилактику и лечение ожирения вовлекаются не только эндокринологи, но и терапевты, кардиологи, гинекологи, гастроэнтерологи и врачи многих других специальностей. Мультидисциплинарная рабочая группа представляет этот проект в многопрофильном журнале с целью объединения усилий нескольких профессиональных ассоциаций, что связано с необходимостью уделить внимание не только самому ожирению, но и коморбидным состояниям. Мы надеемся на конструктивную критику и разностороннее обсуждение проблемы на страницах нашего журнала.

клинические рекомендацииартериальная гипертензиябандажирование желудкабариатрическая / метаболическая хирургиябилиопанкреатическое шунтированиегипокалорийное питаниежелудочное шунтированиелираглутидморбидное ожирениеожирениеорлистатрукавная гастрэктомиясахарный диабет 2 типасибутраминобструктивное апноэ снафизическая активностьпостменопаузанеалкогольная жировая болезнь печенигиперурикемияподагра

guidelinesarterial hypertensiongastric bandingbariatric / metabolic surgerybiliopancreatic diversion (BPD)hypocaloric nutritiongastric bypassliraglutidemorbid obesityobesityorlistatsleeve gastrectomytype 2 diabetessibutraminobstructive sleep apnoephysical activitypostmenopausenon-alcoholic fatty liver diseasehyperuricemiagout

References1

Must A. The Disease Burden Associated With Overweight and Obesity. JAMA. 1999;282(16):1523. doi: https://doi.org/10.1001/jama.282.16.1523

Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. doi: https://doi.org/10.1186/1471-2458-9-88

Lenz M, Richter T, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in Adulthood. Dtsch Aerzteblatt Online. 2009;106:641-648. doi: https://doi.org/10.3238/arztebl.2009.0641

Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995. doi: https://doi.org/10.1002/(sici)1520-6300(1996)8:6<786::aidajhb11>3.0.co;2-i

Forbes GB, Reina JC. Adult lean body mass declines with age: Some longitudinal observations. Metabolism. 1970;19(9):653-663. doi: https://doi.org/10.1016/0026-0495(70)90062-4

Rolland-Cachera MF et al. Body mass index variations — centiles from birth to 87 years. European Journal of Clinical Nutrition. 1991;45:13-21.

Ross R, Shaw KD, Rissanen J, et al. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. Am J Clin Nutr. 1994;59(6):1277-1285. doi: https://doi.org/10.1093/ajcn/59.6.1277

Shen W, Wang Z, Punyanita M, et al. Adipose Tissue Quantification by Imaging Methods: A Proposed Classification. Obes Res. 2003;11(1):5-16. doi: https://doi.org/10.1038/oby.2003.3

Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition.Lancet. 2005;366(9491):1059-1062. doi: https://doi.org/10.1016/S0140-6736(05)67402-8

https://www.who.int/en/news-room/fact-sheets/detail/obesity-andoverweight

Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311(6998):158-161. doi: https://doi.org/10.1136/bmj.311.6998.158

Han TS et al. Waist circumference relates to intra-abdominal fat mass better than waist:hip ratio in women. Proceedings of the Nutrition Society. 1995;54:152A.

Pouliot M-C, Després J-P, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73(7):460-468. doi: https://doi.org/10.1016/0002-9149(94)90676-9

Wormser D, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–1095. doi: https://doi.org/10.1016/S0140-6736(11)60105-0

Fox CS, Massaro JM, Hoffmann U, et al. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments. Circulation. 2007;116(1):39-48. doi: https://doi.org/10.1161/CIRCULATIONAHA.106.675355

Misra A, Jayawardena R, Anoop S. Obesity in South Asia: Phenotype, Morbidities, and Mitigation. Curr Obes Rep. 2019;8(1):43-52. doi: https://doi.org/10.1007/s13679-019-0328-0

Cheng L, Yan W, Zhu L, et al. Comparative analysis of IDF, ATPIII and CDS in the diagnosis of metabolic syndrome among adult inhabitants in Jiangxi Province, China. PLoS One. 2017;12(12):e0189046. doi: https://doi.org/10.1371/journal.pone.0189046

Nishida C, Barba C, Cavalli-Sforza T, et al. Appropriate bodymass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. doi: https://doi.org/10.1016/S0140-6736(03)15268-3

Pan W-H, Yeh W-T. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations. Asia Pac J Clin Nutr. 2008. doi: https://doi.org/10.6133/apjcn.2008.17.3.02

Nam GE, Park HS. Perspective on Diagnostic Criteria for Obesity and Abdominal Obesity in Korean Adults. J Obes Metab Syndr. 2018;27(3):134-142. doi: https://doi.org/10.7570/jomes.2018.27.3.134

Zeng Q, He Y, Dong S, et al. Optimal cut-off values of BMI, waist circumference and waist:height ratio for defining obesity in Chinese adults. Br J Nutr. 2014;112(10):1735-1744. doi: https://doi.org/10.1017/S0007114514002657

Jih J, Mukherjea A, Vittinghoff E, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med (Baltim). 2014;65:1-6. doi: https://doi.org/10.1016/j.ypmed.2014.04.010

Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. EndocrPract. 2016;22(3):1-203. doi: https://doi.org/10.4158/EP161365

Anothaisintawee T, Sansanayudh N, Thamakaison S, et al. Neck Circumference as an Anthropometric Indicator of Central Obesity in Patients with Prediabetes: A Cross-Sectional Study. Biomed Res Int. 2019;2019:1-8. doi: https://doi.org/10.1155/2019/4808541

Qureshi N, Hossain T, Hassan M, et al. Neck circumference as a marker of overweight and obesity and cutoff values for Bangladeshi adults. Indian J Endocrinol Metab. 2017;21(6):803. doi: https://doi.org/10.4103/ijem.IJEM_196_17

ADA. Standarts of medical care in diabetes-2019. Diabetes Care. 2019;24(1):s1-s187.

WHO. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation; 2006.

Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1

Piepoli MF, Hoes AW, Agewall S, et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European. Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-2381.

Chazova IE, Shestakova MV, Zhernakova YV, et al. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Syst Hypertens. 2020;17(1):7-45. (In Russ.). doi: https://doi.org/10.26442/2075082X.2020.1.200051

Chazova IE, Shestakova MV, Zhernakova YV, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47. doi: https://doi.org/10.1093/humrep/deh098

Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(03):479-504. doi: https://doi.org/10.5664/jcsm.6506

Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta-Analysis. J Clin Endocrinol Metab. 2014;99(3):923-931. doi: https://doi.org/10.1210/jc.2013-2409

Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid Function in Humans with Morbid Obesity. Thyroid. 2006;16(1):73-78. doi: https://doi.org/10.1089/thy.2006.16.73

Tiryakioglu O, Ugurlu S, Yalin S, et al. Screening for Cushing’s syndrome in obese patients. Clinics. 2010;65(1):9-13. doi: https://doi.org/10.1590/S1807-59322010000100003

Lammert A, Nittka S, Otto M, et al. Performance of the 1 mg dexamethasone suppression test in patients with severe obesity. Obesity. 2016;24(4):850-855. doi: https://doi.org/10.1002/oby.21442

Janković D, Wolf P, Anderwald C-H, et al. Prevalence of Endocrine Disorders in Morbidly Obese Patients and the Effects of Bariatric Surgery on Endocrine and Metabolic Parameters. Obes Surg. 2012;22(1):62-69. doi: https://doi.org/10.1007/s11695-011-0545-4

Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s Syndrome in Type-2 Diabetes. J Clin Endocrinol Metab. 2003;88(12):5808-5813. doi: https://doi.org/10.1210/jc.2003-030254

Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf). 1996;44(6):717-722. doi: https://doi.org/10.1046/j.1365-2265.1996.737558.x

Steffensen C, Pereira AM, Dekkers OM, Jørgensen JOL. Diagnosis of endocrine disease: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(6):R247-R253. doi: https://doi.org/10.1530/EJE-16-0434

Caetano MSS, Silva RDC, Kater CE. Increased diagnostic probability of subclinical cushing’s syndrome in a population sample of overweight adult patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2007;51(7):1118-1127. doi: https://doi.org/10.1590/S0004-27302007000700015

Fleseriu M, Ludlam WH, Teh SH, Yedinak CG, Deveney C, Sheppard BC. Cushing’s syndrome might be underappreciated in patients seeking bariatric surgery: a plea for screening. Surg Obes Relat Dis. 2009;5(1):116-119. doi: https://doi.org/10.1016/j.soard.2008.09.011

Savastano S, Pivonello R, Colao A. Bariatric surgery for obesity and hidden Cushing syndrome. Surg Obes Relat Dis. 2009;5(1):121-122. doi: https://doi.org/10.1016/j.soard.2008.07.006

Loriaux DL. Diagnosis and Differential Diagnosis of Cushing’s Syndrome. N Engl J Med. 2017;376(15):1451-1459. doi: https://doi.org/10.1056/NEJMra1505550

Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic Hypogonadism in Men With Diabesity. Diabetes Care. 2018;41(7):1516-1525. doi: https://doi.org/10.2337/dc17-2510

Auriemma RS, De Alcubierre D, Pirchio R, et al. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13(2):99-106. doi: https://doi.org/10.1080/17446651.2018.1434412

Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2009;94(3):709-728.

van der Klaauw AA, Farooqi IS. The Hunger Genes: Pathways to Obesity. Cell. 2015;161(1):119-132. doi: https://doi.org/10.1016/j.cell.2015.03.008

Koves IH, Roth C. Genetic and Syndromic Causes of Obesity and its Management. Indian J Pediatr. 2018;85(6):478-485. doi: https://doi.org/10.1007/s12098-017-2502-2

Must A. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393-403. doi: https://doi.org/10.1056/NEJMoa012512

Blundell JE, Dulloo AG, Salvador J, Frühbeck G. Beyond BMI - Phenotyping the Obesities. Obes Facts. 2014;7(5):322-328. doi: https://doi.org/10.1159/000368783

Schwarz P, Lindström J, Kissimova-Scarbeck K, et al. The European Perspective of Type 2 Diabetes Prevention: Diabetes in Europe - Prevention Using Lifestyle, Physical Activity and Nutritional Intervention (DE-PLAN) Project. Exp Clin Endocrinol Diabetes. 2008;116(03):167-172. doi: https://doi.org/10.1055/s-2007-992115

Hainer V, Toplak H, Mitrakou A. Treatment Modalities of Obesity: What fits whom? Diabetes Care. 2008;31(2):S269-S277. doi: https://doi.org/10.2337/dc08-s265.

Sampsel S, May J. Assessment and Management of Obesity and Comorbid Conditions. Dis Manag. 2007;10(5):252-265. doi: https://doi.org/10.1089/dis.2007.105712

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. J Am Coll Cardiol. 2014;63(25):2985-3023. doi: https://doi.org/10.1016/j.jacc.2013.11.004

World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation (WHO Technical Report Series 894). [Internet]. Geneva: 1998. www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/ (cited: 2015 November 30).

Cefalu WT, Bray GA, Home PD, et al. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care. 2015;38(8):1567-1582. doi: https://doi.org/10.2337/dc15-1081

Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines Formedical Care of Patients with Obesity. Endocr Pract. 2016;22:1-203. doi: https://doi.org/10.4158/EP161365.GL

Shai I, Schwarzfuchs D, Henkin Y, et al. Weight Loss with a LowCarbohydrate, Mediterranean, or Low-Fat Diet. N Engl J Med. 2008;359(3):229-241. doi: https://doi.org/10.1056/NEJMoa0708681

Dernini S, Berry EM. Mediterranean Diet: From a Healthy Diet to a Sustainable Dietary Pattern. Front Nutr. 2015;2. doi: https://doi.org/10.3389/fnut.2015.00015

Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi: https://doi.org/10.1056/NEJMoa1800389.

Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17(4):317-335. doi: https://doi.org/10.1111/j.1365-277X.2004.00531.x

Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk Reduction. JAMA. 2005;293(1):43. doi: https://doi.org/10.1001/jama.293.1.43

Sharma M. Behavioural interventions for preventing and treating obesity in adults. Obes Rev. 2007;8(5):441-449. doi: https://doi.org/10.1111/j.1467-789X.2007.00351.x

Lang A, Froelicher ES. Management of Overweight and Obesity in Adults: Behavioral Intervention for Long-Term Weight Loss and Maintenance. Eur J Cardiovasc Nurs. 2006;5(2):102-114. doi: https://doi.org/10.1016/j.ejcnurse.2005.11.002

Moffitt R, Haynes A, Mohr P. Treatment Beliefs and Preferences for Psychological Therapies for Weight Management. J Clin Psychol. 2015;71(6):584-596. doi: https://doi.org/10.1002/jclp.22157

Willis LH, Slentz CA, Bateman LA, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol. 2012;113(12):1831-1837. doi: https://doi.org/10.1152/japplphysiol.01370.2011

Geliebter A, Christopher N, Ochner CN, et al. Obesity-related hormones and metabolic risk factors: a randomized trial of diet plus either strength or aerobic training versus diet alone in overweight participants. J Diabetes Obes. 2015;1:1–7.

Poirier P, Després J-P. Exercise in weight management of obesity. Cardiol Clin. 2001;19(3):459-470. doi: https://doi.org/10.1016/S0733-8651(05)70229-0

Chin S ‐H., Kahathuduwa CN, Binks M. Physical activity and obesity: what we know and what we need to know*. Obes Rev. 2016;17(12):1226-1244. doi: https://doi.org/10.1111/obr.12460

K. Stephens S, J. Cobiac L, Veerman JL. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Prev Med (Baltim). 2014;62:167-178. doi: https://doi.org/10.1016/j.ypmed.2014.02.008

Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6(3):343-368. doi: https://doi.org/10.1586/14779072.6.3.343

Cullen KW, Baranowski T, Owens E, Marsh T, Rittenberry L, de Moor C. Availability, Accessibility, and Preferences for Fruit, 100% Fruit Juice, and Vegetables Influence Children’s Dietary Behavior. Heal Educ Behav. 2003;30(5):615-626. doi: https://doi.org/10.1177/1090198103257254

Hanson NI, Neumark-Sztainer D, Eisenberg ME, et al. Associations between parental report of the home food environment and adolescent intakes of fruits, vegetables and dairy foods. Public Health Nutr. 2005;8(1):77-85. doi: https://doi.org/10.1079/PHN2005661

Duffey KJ, Gordon-Larsen P, Jacobs DR, et al. Differential associations of fast food and restaurant food consumption with 3-y change in body mass index: the Coronary Artery Risk Development in Young Adults Study. Am J Clin Nutr. 2007;85(1):201-208. doi: https://doi.org/10.1093/ajcn/85.1.201

Wing RR, Tate DF, Gorin AA, et al. A Self-Regulation Program for Maintenance of Weight Loss. N Engl J Med. 2006;355(15):1563-1571. doi: https://doi.org/10.1056/NEJMoa061883

Schmidt ME, Haines J, O’Brien A, et al. Systematic Review of Effective Strategies for Reducing Screen Time Among Young Children. Obesity. 2012;20(7):1338-1354. doi: https://doi.org/10.1038/oby.2011.348

Gonzalez-Campoy JM, Castorino K, Ebrahim A, et al. Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults: Cosponsored by the American Association of Clinical Endocrinologists/ The American College of Endocrinology and the Obesity Soci. Endocr Pract. 2013;19(15):1-82. doi: https://doi.org/10.4158/EP13155.GL

AACE/ACE Obesity Task Force. AACE/ACE Position Statement on the Prevention, Diagnosis, and Treatment of Obesity. Endocr Pract. 1998;4:297-350.

Seagle HM, Strain GW, Makris A, Reeves RS. Position of the American Dietetic Association: Weight Management. J Am Diet Assoc. 2009;109(2):330-346. doi: https://doi.org/10.1016/j.jada.2008.11.041

2006 Adult Weight Management EvidenceBased Nutrition Practice Guideline. Available at: https://www.andeal.org/topic.cfm?cat=2798&auth=1.2009

Afshin A, Sur PJ, Fay KA, et al. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;393(10184):1958-1972. doi: https://doi.org/10.1016/S0140-6736(19)30041-8

Yancy WS, Olsen MK, Guyton JR, Bakst RP, Westman EC. A LowCarbohydrate, Ketogenic Diet versus a Low-Fat Diet To Treat Obesity and Hyperlipidemia. Ann Intern Med. 2004;140(10):769. doi: https://doi.org/10.7326/0003-4819-140-10-200405180-00006

Wadden TA, West DS, Neiberg RH, et al. One-year Weight Losses in the Look AHEAD Study: Factors Associated With Success. Obesity. 2009;17(4):713-722. doi: https://doi.org/10.1038/oby.2008.637

Wadden TA, Butryn ML, Byrne KJ. Efficacy of Lifestyle Modification for Long-Term Weight Control. Obes Res. 2004;12(S12):151S-162S. doi: https://doi.org/10.1038/oby.2004.282

Gonzalez-Campoy JM, Castorino K, Ebrahim A, et al. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care. 2002;25(12):2165-2171. doi: https://doi.org/10.2337/diacare.25.12.2165

Perri MG, McAllister DA, Gange JJ, et al. Effects of four maintenance programs on the long-term management of obesity. J Consult Clin Psychol. 1988;56(4):529-534. doi: https://doi.org/10.1037/0022-006X.56.4.529

Sbrocco T, Nedegaard RC, Stone JM, Lewis EL. Behavioral choice treatment promotes continuing weight loss: Preliminary results of a cognitive–behavioral decision-based treatment for obesity. J Consult Clin Psychol. 1999;67(2):260-266. doi: https://doi.org/10.1037/0022-006X.67.2.260

The Practical Guide : Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. [Bethesda, Md.] :National Institutes of Health, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American Association for the Study of Obesity, 2000.

NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998 Sep. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2003/

Biddle SJH, Bengoechea García E, Pedisic Z, et al. Screen Time, Other Sedentary Behaviours, and Obesity Risk in Adults: A Review of Reviews. Curr Obes Rep. 2017;6(2):134-147. doi: https://doi.org/10.1007/s13679-017-0256-9

Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. Longo DL, ed. N Engl J Med. 2017;376(3):254-266. doi: https://doi.org/10.1056/NEJMra1514009

Guh DP, Zhang W, Bansback N, et al. The incidence of comorbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9:88. doi: https://doi.org/10.1186/1471-2458-9-88

Dansinger ML, Gleason JA, Griffith JL. et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk ReductionA Randomized Trial. JAMA. 2005;293(1):43-53. doi: https://doi.org/10.1001/jama.293.1.43

Stephens SK, Cobiac LJ, Veerman JL. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Prev Med (Baltim). 2014;62:167-178. doi: https://doi.org/10.1016/j.ypmed.2014.02.008

Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-1199. doi: https://doi.org/10.1136/bmj.39385.413113.25

100

Avenell A, Broom J, Brown T, et al. Systematic review of the longterm effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess (Rockv). 2004;8(21). doi: https://doi.org/10.3310/hta8210.

101

102

103

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014;129(25 suppl 2):S102-S138. doi: https://doi.org/10.1161/01.cir.0000437739.71477.ee

104

Bray GA. Medical treatment of obesity: The past, the present and the future. Best Pract Res Clin Gastroenterol. 2014;28(4):665-684. doi: https://doi.org/10.1016/j.bpg.2014.07.015

105

Pucci A, Finer N. New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects. Can J Cardiol. 2015;31(2):142-152. doi: https://doi.org/10.1016/j.cjca.2014.11.010

106

Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161. doi: https://doi.org/10.2337/diacare.27.1.155

107

Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diabetes, Obes Metab. 2005;7(6):699-708. doi: https://doi.org/10.1111/j.1463-1326.2005.00483.x

108

Williamson DF, Pamuk E, Thun M, et al. Prospective Study of Intentional Weight Loss and Mortality in Overweight White Men Aged 40-64 Years. Am J Epidemiol. 1999;149(6):491-503. doi: https://doi.org/10.1093/oxfordjournals.aje.a009843

109

James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356(9248):2119-2125. doi: https://doi.org/10.1016/S0140-6736(00)03491-7

110

Dedov II, Melnichenko GA, Troshina EA, et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11(4):335-343. doi: https://doi.org/10.1159/000488880

111

Dedov II, Mel’nichenko GA, Romantsova TI. The strategy of obesity management: the results of All-Russian observational program “Primavera.” Obesity and metabolism. 2016;13(1):36-44. (In Russ.). doi: https://doi.org/10.14341/omet2016136-44

112

Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346:393–403. doi: https://doi.org/10.1056/NEJMoa012512

113

Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi: https://doi.org/10.1056/NEJMoa1411892

114

le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409. doi: https://doi.org/10.1016/s0140-6736(17)30069-7

115

Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. doi: https://doi.org/10.1038/ij o.2016.52

116

Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2013; 37:1443-1451. doi: https://doi.org/10.1038/ijo.2013.120

117

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. doi: https://doi.org/10.1056/NEJMoa1603827

118

Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723. doi: https://doi.org/10.1111/obr.12551.

119

Magkos F, Fraterrigo G, Yoshino J. et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab, 2016;23:1-11. doi: https://doi.org/10.1016/j.cmet.2016.02.005

120

McGuire MT, Wing RR, Hill JO. The prevalence of weight loss maintenance among American adults. Int J Obes Relat Metab Disord. 1999;23:1314-1319. doi: https://doi.org/10.1038/sj.ijo.0801075

121

Dulloo AG, Jacquet J, Girardier L. Poststarvation hyperphagia and body fat overshooting in humans: a role for feedback signals from lean and fat tissues. Am J Clin Nutr. 1997;65(3):717-723. doi: https://doi.org/10.1093/ajcn/65.3.717

122

Roumans NJT, Vink RG, Bouwman FG, et al. Weight-loss stress in subcutaneous adipose tissue is related to weight regain. Int J Obes (Lond). 2017;41(6):894-901. doi: https://doi.org/10.1038/ijo.2016.221

123

Crujeiras AB, Goyenechea E, Abete I, et al. Weight Regain after a Diet-Induced Loss Is Predicted by Higher Baseline Leptin and Lower Ghrelin Plasma Levels. J Clin Endocrinol Metab. 2010;95(11):5037-5044. doi: https://doi.org/10.1210/jc.2009-2566

124

Hinkle W, Cordell M, Leibel R, et al. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One. 2013;8:e59114. doi: https://doi.org/10.1371/journal.pone.0059114.

125

Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med . 2011;365:1597-1604. doi: https://doi.org/10.1056/NEJMoa1105816

126

Kasher-Meron M, Youn DY, Zong H, Pessin JE. Lipolysis defect in white adipose tissue and rapid weight regain. Am J Physiol Metab. 2019;317(2):E185-E193. doi: https://doi.org/10.1152/ajpendo.00542.2018

127

Sparti A, DeLany JP, de la Bretonne JA, et al. Relationship between resting metabolic rate and the composition of the fat-free mass. Metabolism. 1997;46:1225-1230. doi: https://doi.org/10.1016/S0026-0495(97)90222-5

128

Leibel RL, Rosenbaum M, Hirsch J. Changes in Energy Expenditure Resulting from Altered Body Weight. N Engl J Med. 1995;332(10):621-628. doi: https://doi.org/10.1056/NEJM199503093321001

129

Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008;88:906-912. doi: https://doi.org/10.1093/ajcn/88.4.906

130

Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001;21:323-341. doi: https://doi.org/10.1146/annurev.nutr.21.1.323

131

DeJesus RS, Bauer KW, Bradley DP, et al. Experience and expectations of patients on weight loss: The Learning Health system Network experience. Obesity Science & Practice. 2019;5(5):479-486. doi: https://doi.org/10.1002/osp4.364

132

Preuss H, Leister L, Pinnow M, Legenbauer T. Inhibitory control pathway to disinhibited eating: A matter of perspective? Appetite. 2019;141(2):104297. doi: https://doi.org/10.1016/j.appet.2019.05.028

133

Vink RG, Roumans NJT, Arkenbosch LAJ, et al. The effect of rate of weight loss on long-term weight regain in adults with overweight and obesity. Obesity. 2016;24(2):321-327. doi: https://doi.org/10.1002/oby.21346

134

135

Bray GA, Heisel WE, Afshin A, et al. The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocr Rev. 2018;39(2):79-132. doi: https://doi.org/10.1210/er.2017-00253

136

Aller EE, Larsen TM, Claus H, et al. Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index: the DIOGENES trial 12-month results. Int. J. Obes. (Lond.). 2014;38:1511-1517. doi: https://doi.org/10.1038/ijo.2014.52

137

Varkevisser RDM, van Stralen MM, Kroeze W, et al. Determinants of weight loss maintenance: a systematic review. Obes Rev. 2019;20(2):171-211. doi: https://doi.org/10.1111/obr.12772

138

Schoeller DA, Shay K, Kushner RF. et al. How much physical activity is needed to minimize weight gain in previously obese women? Am J Clin Nutr. 1997;66(3):551-556. doi: https://doi.org/10.1093/ajcn/66.3.551.

139

Ostendorf DM, Caldwell AE, Creasy SA, et al. Physical Activity Energy Expenditure and Total Daily Energy Expenditure in Successful Weight Loss Maintainers. Obesity (Silver Spring). 2019;27(3):496-504. doi: https://doi.org/10.1002/oby.22373

140

James WTP, Astrup A, Finer N, et al. The STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119–2125. doi: https://doi.org/10.1016/S0140-6736(00)03491-7

141

Richelsen B, Tonstad S, Rössner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-lowenergy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30(1):27-32. doi: https://doi.org/10.2337/dc06-0210

142

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after lowcalorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-51. doi: https://doi.org/10.1038/ijo.2013.120.

143

Dutton GR, Gowey MA, Tan F. Comparison of an alternative schedule of extended care contacts to a self-directed control: a randomized trial of weight loss maintenance. Int J Behav Nutr Phys Act. 2017;14(1):107. doi: https://doi.org/10.1186/s12966-017-0564-1

144

Wing RR, Tate DF, Gorin AA, et al. A Self-Regulation Program for Maintenance of Weight Loss. N Engl J Med. 2006;355(15):1563-1571. doi: https://doi.org/10.1056/NEJMoa061883

145

Ostendorf DM, Lyden K, Pan Z, et al. Objectively measured physical activity and sedentary behavior in successful weight loss maintainers. Obesity (Silver Spring). 2018;26(1):53-60. doi: https://doi.org/10.1002/oby.22052

146

Crain AL, Sherwood NE, Martinson BC, Jeffery RW. Mediators of Weight Loss Maintenance in the Keep It Off Trial. Ann Behav Med. 2018;52(1):9-18. doi: https://doi.org/10.1007/s12160-017-9917-x

147

Kim K-B, Kim K, Kim C, et al. Effects of Exercise on the Body Composition and Lipid Profile of Individuals with Obesity: A Systematic Review and Meta-Analysis. J Obes Metab Syndr. 2019;28(4):278-294. doi: https://doi.org/10.7570/jomes.2019.28.4.278

148

Thorogood A, Mottillo S, Shimony A, et al. Isolated Aerobic Exercise and Weight Loss: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Med. 2011;124(8):747-755. doi: https://doi.org/10.1016/j.amjmed.2011.02.037

149

Johns DJ, Hartmann-Boyce J, Jebb SA, Aveyard P. Diet or Exercise Interventions vs Combined Behavioral Weight Management Programs: A Systematic Review and Meta-Analysis of Direct Comparisons. J Acad Nutr Diet. 2014;114(10):1557-1568. doi: https://doi.org/10.1016/j.jand.2014.07.005

150

Hamasaki H. Physical Activity and Obesity in Adults. In: Adiposity - Epidemiology and Treatment Modalities. Vol 13. InTech; 2017:36-44. doi: https://doi.org/10.5772/64672

151

Conn VS, Hafdahl A, Phillips LJ, et al. Impact of Physical Activity Interventions on Anthropometric Outcomes: Systematic Review and Meta-Analysis. J Prim Prev. 2014;35(4):203-215. doi: https://doi.org/10.1007/s10935-014-0352-5

152

Fildes A, Charlton J, Rudisill C, et al. Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records. Am J Public Health. 2015;105(9):e54-e59. doi: https://doi.org/10.2105/AJPH.2015.302773

153

Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. Circ Res. 2016;118(11):1752-1770. doi: https://doi.org/10.1161/CIRCRESAHA.115.306883

154

Dunn AL. Effectiveness of Lifestyle Physical Activity Interventions to Reduce Cardiovascular Disease. Am J Lifestyle Med. 2009;3(1):11S-18S. doi: https://doi.org/10.1177/1559827609336067

155

Kushner RF. Weight Loss Strategies for Treatment of Obesity. Prog Cardiovasc Dis. 2014;56(4):465-472. doi: https://doi.org/10.1016/j.pcad.2013.09.005

156

Obert J, Pearlman M, Obert L, Chapin S. Popular Weight Loss Strategies: a Review of Four Weight Loss Techniques. Curr Gastroenterol Rep. 2017;19(12):61. doi: https://doi.org/10.1007/s11894-017-0603-8

157

Jelleyman C, Yates T, O’Donovan G, et al. The effects of highintensity interval training on glucose regulation and insulin resistance: a meta-analysis. Obes Rev. 2015;16(11):942-961. doi: https://doi.org/10.1111/obr.12317

158

Wewege M, van den Berg R, Ward RE, Keech A. The effects of highintensity interval training vs. moderate-intensity continuous training on body composition in overweight and obese adults: a systematic review and meta-analysis. Obes Rev. 2017;18(6):635-646. doi: https://doi.org/10.1111/obr.12532

159

Türk Y, Theel W, Kasteleyn MJ, et al. High intensity training in obesity: a Meta-analysis. Obes Sci Pract. 2017;3(3):258-271. doi: https://doi.org/10.1002/osp4.109

160

De Feo P. Is high-intensity exercise better than moderate-intensity exercise for weight loss? Nutr Metab Cardiovasc Dis. 2013;23(11):1037-1042. doi: https://doi.org/10.1016/j.numecd.2013.06.002

161

Sword DO. Exercise as a Management Strategy for the Overweight and Obese. Strength Cond J. 2012;34(5):47-55. doi: https://doi.org/10.1519/SSC.0b013e31826d9403

162

Fogelholm M, Stallknecht B, Van Baak M. ECSS position statement: Exercise and obesity. Eur J Sport Sci. 2006;6:15–24. doi: https://doi.org/10.1080/17461390600563085

163

Dedov II, Shestakova MV, Mayorov AYu et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1

164

Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care. 2000;23(8):1108-1112. doi: https://doi.org/10.2337/diacare.23.8.1108

165

Simmons RK, Griffin SJ, Witte DR et al. Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia. 2017;60(11):2183-2191. doi: https://doi.org/10.1007/s00125-017-4323-2

166

Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia. 2017;60(11):2192-2199. doi: https://doi.org/10.1007/s00125-017-4299-y

167

Sortsø C, Komkova A, Sandbæk A, et al. Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia. 2018;61:1306. doi: https://doi.org/10.1007/s00125-018-4594-2

168

Mottalib A, Kasetty M, Mar JY, et al. Weight Management in Patients with Type 1 Diabetes and Obesity. Curr Diab Rep. 2017;17:92. doi: https://doi.org/10.1007/s11892-017-0918-8

169

Dedov II, Mel’nichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and metabolism. 2018;15(1):53-70. (In Russ.). doi: https://doi.org/10.14341/omet2018153-70

170

Wing RR, Lang W, Wadden TA, et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care. 2011;34(7):1481-1486. doi: https://doi.org/10.2337/dc10-2415

171

Johnston BC, Kanters S, Bandayrel K, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. A Meta-analysis. JAMA. 2014;312(9):923-933. doi: https://doi.org/10.1001/jama.2014.10397

172

Sacks FM, Bray GA, Carey VJ, et al. Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates. N Engl J Med. 2009;360(9):859-873. doi: https://doi.org/10.1056/NEJMoa0804748

173

Bell KJ, Barclay AW, Petocz P, et al. Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and metaanalysis. Lancet Diabetes Endocrinol. 2014;2(2):133-140. doi: https://doi.org/10.1016/S2213-8587(13)70144-X

174

D’Alessandro A, De Pergola G. Mediterranean Diet Pyramid: A Proposal for Italian People. Nutrients. 2014;6:4302-4316. doi: https://doi.org/10.3390/nu6104302.

175

176

Esposito K, Maiorino MI, Bellastella G, et al. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open. 2015;5(8):e008222. doi: https://doi.org/10.1136/bmjopen-2015-008222

177

Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019;12(1):40-66. doi: https://doi.org/10.1159/000496183

178

Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861-877. doi: https://doi.org/10.2337/dc16-0236

179

Aminian A, Brethauer SA, Andalib A? et al. Individualized Metabolic Surgery Score: Procedure Selection Based on Diabetes Severity. Ann Surg. 2017;266(4):650-657. doi: https://doi.org/10.1097/SLA.0000000000002407

180

Busetto L, Dicker D, Azran C, et al. Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obes Facts. 2017;10(6):597-632. doi: https://doi.org/10.1159/000481825

181

Hussain A. The effect of metabolic surgery on type 1 diabetes: meta-analysis. Arch Endocrinol Metab. 2018;62(2):172-178. doi: https://doi.org/10.20945/2359-3997000000021

182

World Health Organization. Noncommunicable Diseases Country Profiles 2018. Russian Federation. Available at: https://www.who.int/nmh/countries/2018/rus_en.pdf?ua=1

183

Norman JE. The adverse effects of obesity on reproduction. Reproduction. 2010;140(3):343-345. doi: https://doi.org/10.1530/REP-10-0297

184

Pasquali R, Gambineri A, Pagotto U. Review article: The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG An Int J Obstet Gynaecol. 2006;113(10):1148-1159. doi: https://doi.org/10.1111/j.1471-0528.2006.00990.x

185

Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. Reprod Biomed Online. 2006;12(5):542-551. doi: https://doi.org/10.1016/S1472-6483(10)61179-0

186

Pasquali R. Obesity and reproductive disorders in women. Hum Reprod Update. 2003;9(4):359-372. doi: https://doi.org/10.1093/humupd/dmg024

187

Jain A, Polotsky AJ, Rochester D, et al. Pulsatile Luteinizing Hormone Amplitude and Progesterone Metabolite Excretion Are Reduced in Obese Women. J Clin Endocrinol Metab. 2007;92(7):2468-2473. doi: https://doi.org/10.1210/jc.2006-2274

188

Castillo-Martínez L, López-Alvarenga JC, Villa AR, González-Barranco J. Menstrual cycle length disorders in 18- to 40-y-old obese women. Nutrition. 2003;19(4):317-320. doi: https://doi.org/10.1016/S0899-9007(02)00998-X

189

Polotsky AJ, Hailpern SM, Skurnick JH, et al. Association of adolescent obesity and lifetime nulliparity—The Study of Women’s Health Across the Nation (SWAN). Fertil Steril. 2010;93(6):2004-2011. doi: https://doi.org/10.1016/j.fertnstert.2008.12.059

190

Kuchenbecker WKH, Groen H, Zijlstra TM, et al. The Subcutaneous Abdominal Fat and Not the Intraabdominal Fat Compartment Is Associated with Anovulation in Women with Obesity and Infertility. J Clin Endocrinol Metab. 2010;95(5):2107-2112. doi: https://doi.org/10.1210/jc.2009-1915

191

Morán C, Hernández E, Ruíz JE, et al. Upper Body Obesity and Hyperinsulinemia Are Associated with Anovulation. Gynecol Obstet Invest. 1999;47(1):1-5. doi: https://doi.org/10.1159/000010052

192

Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. Hum Reprod. 2006;22(2):414-420. doi: https://doi.org/10.1093/humrep/del400

193

Jensen TK, Scheike T, Keiding N, Schaumburg I, Grandjean P. Fecundability in Relation to Body Mass and Menstrual Cycle Patterns. Epidemiology. 1999;10(4):422-428. doi: https://doi.org/10.1097/00001648-199907000-00014

194

Zaadstra BM, Seidell JC, Van Noord PA, et al. Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. BMJ. 1993;306(6876):484-487. doi: https://doi.org/10.1136/bmj.306.6876.484

195

Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical Activity, Body Mass Index, and Ovulatory Disorder Infertility. Epidemiology. 2002;13(2):184-190. doi: https://doi.org/10.1097/00001648-200203000-00013

196

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults — The Evidence Report. National Institutes of Health. Obesity research. 1998;6(Suppl 2):51S–209S.

197

Selter J, Wen T, Palmerola KL, et al. Life-threatening complications among women with severe ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 2019;220(6):575.e1-575.e11. doi: https://doi.org/10.1016/j.ajog.2019.02.009

198

Siddiqui A, Azria E, Howell EA, et al. Associations between maternal obesity and severe maternal morbidity: Findings from the French EPIMOMS population‐based study. Paediatr Perinat Epidemiol. 2019;33(1):7-16. doi: https://doi.org/10.1111/ppe.12522

199

Belitsina L.V. Ozhirenie i reproduktivnoe zdorov'e (obzornaya stat'ya). Zhurnal assotsiatsii spetsialistov v oblasti reproduktivnogo zdorov'ya. 2012;(3):3-25. (In Russ.).

200

Podzolkova N.M., Ageeva M.I., Skvortsova M.Yu., et al. Techenie beremennosti i perinatal'nye iskhody u zhenshchin s narusheniyami zhirovogo obmena. Akusherstvo i Ginekologiya. 2011;(6):86-92. (In Russ.).

201

Gaudet L, Ferraro ZM, Wen SW, Walker M. Maternal Obesity and Occurrence of Fetal Macrosomia: A Systematic Review and Meta-Analysis. Biomed Res Int. 2014;2014:1-22. doi: https://doi.org/10.1155/2014/640291

202

Institute of Medicine and National Research Council. 2009. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: The National Academies Press. doi: https://doi.org/10.17226/12584

203

Mahutte N, Kamga-Ngande C, Sharma A, Sylvestre C. Obesity and Reproduction. J Obstet Gynaecol Canada. 2018;40(7):950-966. doi: https://doi.org/10.1016/j.jogc.2018.04.030

204

Holton S, Fisher J, Nguyen H, et al. Pre-pregnancy body mass index and the risk of antenatal depression and anxiety. Women and Birth. 2019;32(6):e508-e514. doi: https://doi.org/10.1016/j.wombi.2019.01.007

205

Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity’s impact. Fertil Steril. 2017;107(4):840-847. doi: https://doi.org/10.1016/j.fertnstert.2017.01.017

206

Teede H, Misso M, Costello M, et al. International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018. Available at: https://www.monash.edu/__data/assets/pdf_file/0004/1412644/PCOS_Evidence-Based-Guidelines_20181009.pdf

207

Maged AM, Fahmy RM, Rashwan H, et al. Effect of body mass index on the outcome of IVF cycles among patients with poor ovarian response. Int J Gynecol Obstet. 2019;144(2):161-166. doi: https://doi.org/10.1002/ijgo.12706

208

Koning AMH, Mutsaerts MAQ, Kuchenbecher WKH, et al. Complications and outcome of assisted reproduction technologies in overweight and obese women. Hum Reprod. 2012;27(2):457-467. doi: https://doi.org/10.1093/humrep/der416

209

Banker M, Sorathiya D, Shah S. Effect of Body Mass Index on the Outcome of In-Vitro Fertilization/Intracytoplasmic Sperm Injection in Women. J Hum Reprod Sci. 2017;10(1):37-43. doi: https://doi.org/10.4103/jhrs.JHRS_75_16

210

Frankenthal D, Hirsh-Yechezkel G, Boyko V, et al. The effect of body mass index (BMI) and gestational weight gain on adverse obstetrical outcomes in pregnancies following assisted reproductive technology as compared to spontaneously conceived pregnancies. Obes Res Clin Pract. 2019;13(2):150-155. doi: https://doi.org/10.1016/j.orcp.2018.11.239

211

Kolotkin RL, Zunker C, Østbye T. Sexual Functioning and Obesity: A Review. Obesity. 2012;20(12):2325-2333. doi: https://doi.org/10.1038/oby.2012.104

212

Steffen KJ, King WC, White GE, et al. Changes in Sexual Functioning in Women and Men in the 5 Years After Bariatric Surgery. JAMA Surg. 2019;154(6):487. doi: https://doi.org/10.1001/jamasurg.2018.1162

213

Yao K, Bian C, Zhao X. Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy. Exp Ther Med. 2017;14(2):1271-1276. doi: https://doi.org/10.3892/etm.2017.4642

214

Rodgers R, Avery J, Moore V, et al. Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocr Connect. February 2019. doi: https://doi.org/10.1530/EC-18-0502

215

MacKintosh ML, Crosbie EJ. Prevention Strategies in Endometrial Carcinoma. Curr Oncol Rep. 2018;20(12):101. doi: https://doi.org/10.1007/s11912-018-0747-1

216

Benedetto C, Salvagno F, Canuto EM, Gennarelli G. Obesity and female malignancies. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):528-540. doi: https://doi.org/10.1016/j.bpobgyn.2015.01.003

217

Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011;22(4):145-152. doi: https://doi.org/10.1016/j.tem.2011.01.005

218

Gottschau M, Kjaer SK, Jensen A, et al. Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study. Gynecol Oncol. 2015;136(1):99-103. doi: https://doi.org/10.1016/j.ygyno.2014.11.012

219

Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am J Obstet Gynecol. 2016;214(6):689.e1-689.e17. doi: https://doi.org/10.1016/j.ajog.2016.01.175

220

Bellver J, Martínez-Conejero JA, Labarta E, et al. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. Fertil Steril. 2011;95(7):2335-2341.e8. doi: https://doi.org/10.1016/j.fertnstert.2011.03.021

221

Hillers-Ziemer LE, Arendt LM. Weighing the Risk: effects of Obesity on the Mammary Gland and Breast Cancer Risk. J Mammary Gland Biol Neoplasia. 2020;25(2):115-131. doi: https://doi.org/10.1007/s10911-020-09452-5

222

Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D. Insulin and IGFs in Obesity-Related Breast Cancer. J Mammary Gland Biol Neoplasia. 2013;18(3-4):277-289. doi: https://doi.org/10.1007/s10911-013-9303-7

223

Klinicheskie rekomendatsii Rossiiskoi assotsiatsii endokrinologov i Rossiiskogo obshchestva bariatricheskikh khirurgov «Lechenie ozhireniya u vzroslykh», 2020 (In Russ.). Available at: http://cr.rosminzdrav.ru/schema/28

224

Morgante G, Massaro MG, Di Sabatino A, et al. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecol Endocrinol. 2018;34(1):4-9. doi: https://doi.org/10.1080/09513590.2017.1370644

225

Committee Opinion No. 650. Physical Activity and Exercise During Pregnancy and the Postpartum Period. Obstet Gynecol. 2015;126(6):e135-e142. doi: https://doi.org/10.1097/AOG.0000000000001214

226

Muktabhant B, Lawrie TA, Lumbiganon P, Laopaiboon M. Diet or exercise, or both, for preventing excessive weight gain in pregnancy. Cochrane Database Syst Rev. 2015;(6). doi: https://doi.org/10.1002/14651858.CD007145.pub3

227

Artal R. Guidelines of the American College of Obstetricians and Gynecologists for exercise during pregnancy and the postpartum period. Br J Sports Med. 2003;37(1):6-12. doi: https://doi.org/10.1136/bjsm.37.1.6

228

National Institute for Health and Clinical Excellence. NICE public health guidance 27: weight management before, during and after pregnancy. London, United Kingdom: NICE, 2010. Available at: https://www.nice.org.uk/guidance/ph27

229

Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364-379. doi: https://doi.org/10.1016/j.fertnstert.2018.05.004

230

Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complement Altern Med. 2017;17(1):500. doi: https://doi.org/10.1186/s12906-017-2011-x

231

Kwon C-Y, Lee B, Park KS. Oriental herbal medicine and moxibustion for polycystic ovary syndrome. Medicine (Baltimore). 2018;97(43):e12942. doi: https://doi.org/10.1097/MD.0000000000012942

232

Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. Klinicheskie rekomendatsii MZ RF, 2016 (In Russ.).

233

Rekomendatsii po vedeniyu bol’nykh s metabolicheskim sindromom MZ RF, 2013 (In Russ.).

234

Sukhikh GT, Smetnik VP, Andreeva EN, et al. Menopauzal’naya gormonoterapiya i sokhranenie zdorov’ya zhenshchin v zrelom vozraste. Klinicheskie rekomendatsii (protokol lecheniya), Moskva, 2016. (In Russ.).

235

Lambrinoudaki I, Augoulea A, Armeni E, et al. Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric. 2012;15(4):350-357. doi: https://doi.org/10.3109/13697137.2011.618564

236

Lee SW, Jo HH, Kim MR, Kwon DJ, You YO, Kim JH. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet. 2012;285(2):541-548. doi: https://doi.org/10.1007/s00404-011-2016-5

237

Andreeva EN, Grigoryan OR, Menopauza pri ozhirenii/ Nauchno-prakticheskoe rukovodstvo (pod red. Akademika RAN Dedova I.I.). M.: 2018. S11 (In Russ.).

238

Smetnik VP. Medicina klimakterija. Jaroslavl’: Litera, 2006. S. 848. (in Russ.).

239

Lobo RA, Davis SR, De Villiers TJ, et al. Prevention of diseases after menopause. Climacteric. 2014;17(5):540-556. doi: https://doi.org/10.3109/13697137.2014.933411

240

Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi: https://doi.org/10.3109/13697137.2015.1129166

241

Neves-e-Castro M, Birkhauser M, Samsioe G, et al. EMAS position statement: The ten point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88-92. doi: https://doi.org/10.1016/j.maturitas.2015.02.003

242

National Institute for Health and Clinical Excellence. Menopause: Diagnosis and Management (NG23) 2015. Available at: https://www.nice.org.uk/guidance/ng23/resources/menopausediagnosis-andmanagement-1837330217413

243

Howe M, Leidal A, Montgomery D, Jackson E. Role of Cigarette Smoking and Gender in Acute Coronary Syndrome Events. Am J Cardiol. 2011;108(10):1382-1386. doi: https://doi.org/10.1016/j.amjcard.2011.06.059

244

Luo J, Rossouw J, Margolis KL. Smoking Cessation, Weight Change, and Coronary Heart Disease Among Postmenopausal Women With and Without Diabetes. JAMA. 2013;310(1):94. doi: https://doi.org/10.1001/jama.2013.6871

245

Kline J, Tang A, Levin B. Smoking, alcohol and caffeine in relation to two hormonal indicators of ovarian age during the reproductive years. Maturitas. 2016;92:115-122. doi: https://doi.org/10.1016/j.maturitas.2016.07.010

246

WHO Consultation on Obesity (1997: Geneva S, Diseases WHOD of N, World Health Organization. Programme of Nutrition F and RH. Obesity: preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. https://apps.who.int/iris/handle/10665/63854

247

Stallings DT, Kraenzle Schneider J. Motivational Interviewing and Fat Consumption in Older Adults: A Meta-Analysis. J Gerontol Nurs. 2018;44(11):33-43. doi: https://doi.org/10.3928/00989134-20180817-01

248

Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2014;129(25 suppl 2):S76-S99. doi: https://doi.org/10.1161/01.cir.0000437740.48606.d1

249

Ladabaum U, Mannalithara A, Myer PA, Singh G. Obesity, Abdominal Obesity, Physical Activity, and Caloric Intake in US Adults: 1988 to 2010. Am J Med. 2014;127(8):717-727.e12. doi: https://doi.org/10.1016/j.amjmed.2014.02.026

250

U.S. Department of Health and Human Services. 2008 Physical activity guidelines for Americans: Be Active, Healthy and Happy! US Dep Heal Hum Serv. 2008. Available at: https://health.gov/our-work/physical-activity/current-guidelines

251

Effektivnost’ terapii Reduksinom patsientok s ozhireniem starshe 40 let pri nalichii soputstvuyushchikh ginekologicheskikh zabolevanii. Klinicheskii otchet, programma Primavera, 2016. (In Russ.).

252

Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause. Menopause. 2014;21(9):924-932. doi: https://doi.org/10.1097/GME.0000000000000196

253

Kostromina AA, Radzinskii VE, Khamoshina MB, et al. Faktory riska razvitiya klimaktericheskogo sindroma tyazheloi stepeni: klinikostatisticheskoe issledovanie. Doktor.Ru. 2017.9(138):12–16. (In Russ.).

254

Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. doi: https://doi.org/10.1210/jc.2015-2236

255

WHO. Obesity and overweight. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight

256

Sturm R. Increases in Clinically Severe Obesity in the United States, 1986-2000. Arch Intern Med. 2003;163(18):2146. doi: https://doi.org/10.1001/archinte.163.18.2146

257

Kontsevaya A, Shalnova S, Deev A, et al. Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. Obes Facts. 2019;12(1):103-114. doi: https://doi.org/10.1159/000493885

258

Butrova SA. Ot epidemii ozhireniya k epidemii sakharnogo diabeta. Mezhdunarodnyi endokrinologicheskii zhurnal. 2013;(50)2:45-50. (In Russ.).

259

Kalinchenko SYu, Tyuzikov IA, Vorslov LO. Ozhirenie, insulinorezistentnost’ i reproduktivnoe zdorov’e muzhchiny: patogeneticheskie vzaimodeistviya i sovremennaya patogeneticheskaya farmakologiya. Effektivnaya farmakoterapiya. 2015;27:66-79. (In Russ.).

260

Ametov AS, Demidova TYu, Kochergina II. Effektivnost’ preparatov metformina v lechenii sakharnogo diabeta 2 tipa. Meditsinskii sovet. 2016;3:30-36. (In Russ.).

261

Kogan MI, Vorob’ev SV, Khripun IA, et al. Testosteron: ot seksual’nosti k metabolicheskomu kontrolyu. M.: Feniks; 2017. (In Russ.).

262

Wu F-Z, Wu CC, Kuo P-L, Wu M-T. Differential impacts of cardiac and abdominal ectopic fat deposits on cardiometabolic risk stratification. BMC Cardiovasc Disord. 2016;16(1):20. doi: https://doi.org/10.1186/s12872-016-0195-5

263

Pandolfi JB, Ferraro AA, Sananez I, et al. ATP-Induced Inflammation Drives Tissue-Resident Th17 Cells in Metabolically Unhealthy Obesity. J Immunol. 2016;196(8):3287-3296. doi: https://doi.org/10.4049/jimmunol.1502506

264

Eckel RH, Jakicic JM, Ard JD, et al. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. N Engl J Med. 2013;369(25):2455-2457. doi: https://doi.org/10.1056/NEJMc1313169

265

Corona G, Mannucci E, Ricca V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl. 2009;32(6):720-728. doi: https://doi.org/10.1111/j.1365-2605.2009.00952.x

266

Svartberg J, von Mühlen D, Sundsfjord J, Jorde R. Waist Circumference and Testosterone Levels in Community Dwelling Men. The Tromsø Study. Eur J Epidemiol. 2003;19(7):657-663. doi: https://doi.org/10.1023/B:EJEP.0000036809.30558.8f

267

Rozhivanov RV. Syndrome of hypogonadism in males. Obesity and metabolism. 2014;11(2):30-34. (In Russ.) doi: https://doi.org/10.14341/omet2014230-34

268

Rozhivanov RV, Shurdumova BO, Parfenova NS, Savel’eva LV. Kompleksnyy podkhod k lecheniyu ozhireniyai metabolicheskogo sindroma u muzhchin. Obesity and metabolism. 2009;6(4):38-41. (In Russ.) doi: https://doi.org/10.14341/2071-8713-4877

269

Rozhivanov RV. Endokrinnye narusheniya polovoi funktsii u muzhchin. In: Ratsional’naya farmakoterapiya zabolevanii endokrinnoi sistemy i narushenii obmena veshchestv. Dedov II, Mel’nichenko G.A., editors. Vtoroe izdanie, ispravlennoe i dopolnennoe. Moscow; 2013: 754-775. (In Russ.).

270

Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967-981. doi: https://doi.org/10.1007/s40618-016-0480-2

271

Cameron JL, Jain R, Rais M, et al. Perpetuating effects of androgen deficiency on insulin resistance. Int J Obes. 2016;40(12):1856-1863. doi: https://doi.org/10.1038/ijo.2016.148

272

Vasil’kova ON, Mokhort TV, Rozhko AV. Vozrastnoi androgennyi defitsit, metabolicheskii sindrom i sakharnyi diabet 2-go tipa: est’ li vzaimosvyaz’? Meditsinskie novosti. 2008;3:14-17. (In Russ.)

273

Dzantieva EO, Gusova ZR, Khripun IA, Vorob’ev SV. Osobennosti patogeneticheskogo vliyaniya androgennogo defitsita na formirovanie narushenii uglevodnogo obmena u muzhchin s ozhireniem. Endokrinologiya: Novosti. Mneniya. Obuchenie. 2017;4(21):84-94. (In Russ.).

274

Mamedov MN. Erektil’naya disfunktsiya, androgendefitsitnoe sostoyanie i serdechno-sosudistye zabolevaniya: kompleksnyi podkhod k problemam muzhskogo zdorov’ya. Nauchno-metodicheskoe posobie. Moscow: Med. kniga; 2008. (In Russ.).

275

Zhang W-J, Chen L-L, Zheng J, et al. Association of adult weight gain and nonalcoholic fatty liver in a cross-sectional study in Wan Song Community, China. Brazilian J Med Biol Res. 2014;47(2):151-156. doi: https://doi.org/10.1590/1414-431X20133058

276

Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: https://doi.org/10.1056/NEJMoa0911101

277

Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513

278

Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2011;25(2):221-238. doi: https://doi.org/10.1016/j.beem.2010.08.013

279

Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(3 Suppl):14-22.

280

Bhasin S, Pencina M, Jasuja GK, et al. Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts. J Clin Endocrinol Metab. 2011;96(8):2430-2439. doi: https://doi.org/10.1210/jc.2010-3012

281

Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testoserone measurements performed by mass spectrometry methods. Steroids. 2009;74(6):498-503. doi: https://doi.org/10.1016/j.steroids.2009.01.004

282

Rozhivanov R.V., Kurbatov D.G., Kravtsova N.S. Differential and diagnostic, predictive and therapeutic value of test with clomifene in men with a Hypogonadizm. Problems of Endocrinology. 2016;62(1):35-37. (In Russ.). doi: https://doi.org/10.14341/probl201662135-37

283

Rozhivanov RV. Effektivnaya terapiya i oshibki v lechenii endokrinnykh narushenii v andrologii. In: Endokrinologiya. Farmakoterapiya bez oshibok. Dedov II, Mel’nichenko GA, editors. Moscow; 2013: 615-625. (In Russ.).

284

Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. doi: https://doi.org/10.1111/bju.13337

285

Tracz MJ, Sideras K, Boloña ER, et al. Testosterone Use in Men and Its Effects on Bone Health. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Endocrinol Metab. 2006;91(6):2011-2016. doi: https://doi.org/10.1210/jc.2006-0036

286

Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf ). 2005;63(3):280-293. doi: https://doi.org/10.1111/j.1365-2265.2005.02339.x

287

Moon DG, Park MG, Lee SW, et al. The Efficacy and Safety of Testosterone Undecanoate (Nebido®) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study. J Sex Med. 2010;7(6):2253-2260. doi: https://doi.org/10.1111/j.1743-6109.2010.01765.x

288

Basaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412.

289

Johansen Taber. Male breast cancer: Risk factors, diagnosis, and management (Review). Oncol Rep. 2010;24(5):1115-1120. doi: https://doi.org/10.3892/or_00000962

290

Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21(1):9-23. doi: https://doi.org/10.1038/ijir.2008.31

291

Marks LS, Mazer NA, Mostaghel E, et al. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism. JAMA. 2006;296(19):2351. doi: https://doi.org/10.1001/jama.296.19.2351

292

Medras M, Alicja F, Pawel J, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-265. doi: https://doi.org/10.1007/s10549-005-9074-y

293

Fernández-Balsells MM, Murad MH, Lane M, et al. Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: https://doi.org/10.1210/jc.2009-2575

294

Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi: https://doi.org/10.1517/14740338.2014.950653

295

Calof OM, Singh AB, Lee ML, et al. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials. Journals Gerontol Ser A Biol Sci Med Sci. 2005;60(11):1451-1457. doi: https://doi.org/10.1093/gerona/60.11.1451

296

Basaria S, Coviello AD, Travison TG, et al. Adverse Events Associated with Testosterone Administration. N Engl J Med. 2010;363(2):109-122. doi: https://doi.org/10.1056/NEJMoa1000485

297

Saad F, Aversa A, Isidori AM, et al. Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675-685. doi: https://doi.org/10.1530/EJE-11-0221

298

McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi: https://doi.org/10.1111/j.1365-2141.2005.05535.x

299

Rozhivanov R.V., Kurbatov D.G. Hematological and urological aspects of the safety of androgen substitution therapy using long-acting testosterone undecanoate in patients with hypogonadism. Problems of Endocrinology. 2009;55(6):31-35. (In Russ.). doi: https://doi.org/10.14341/probl200955631-35

300

Morgentaler A, Morales A. Should Hypogonadal Men With Prostate Cancer Receive Testosterone? J Urol. 2010;184(4):1257-1260. doi: https://doi.org/10.1016/j.juro.2010.07.010

301

Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920-922. doi: https://doi.org/10.1097/01.ju.0000136269.10161.32

302

Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536-541. doi: https://doi.org/10.1002/cncr.22438

303

Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract. 2014;8(4):e339-e349. doi: https://doi.org/10.1016/j.orcp.2013.10.005

304

Saad F, Haider A, Doros G, Traish A. Long‐term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity. 2013;21(10):1975-1981. doi: https://doi.org/10.1002/oby.20407

305

Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes. 2013;3(3-4):73-83. doi: https://doi.org/10.1111/cob.12022

306

Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6pt1):528-540. doi: https://doi.org/10.1111/j.1365-2605.2010.01117.x

307

Haider A, Yassin A, Doros G, Saad F. Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes. Int J Endocrinol. 2014;2014:1-15. doi: https://doi.org/10.1155/2014/683515

308

Aversa A, Bruzziches R, Francomano D, et al. Effects of Testosterone Undecanoate on Cardiovascular Risk Factors and Atherosclerosis in Middle-Aged Men with Late-Onset Hypogonadism and Metabolic Syndrome: Results from a 24-month, Randomized, Double-Blind, Placebo-Controlled Study. J Sex Med. 2010;7(10):3495-3503. doi: https://doi.org/10.1111/j.1743-6109.2010.01931.x

309

Jones TH, Arver S, Behre HM, et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care. 2011;34(4):828-837. doi: https://doi.org/10.2337/dc10-1233

310

Strollo F, Strollo G, Morè M, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male. 2013;16(2):33-37. doi: https://doi.org/10.3109/13685538.2013.773305

311

Shalnova SA, Deev AD, Balanova YuA, и др. Twenty years trends of obesity and arterial hypertension and their association in Russia. Cardiovascular Therapy and Prevention. 2017;16(4):4-10. (In Russ.). doi: https://doi.org/10.15829/1728-8800-2017-4-4-10

312

Balanova YA, Shalnova SA, Deev AD, et al. Obesity in russian population — prevalence and association with the non-communicable diseases risk factors. Russian Journal of Cardiology. 2018;(6):123-130. (In Russ.). doi: https://doi.org/10.15829/1560-4071-2018-6-123-130

313

Kannel WB. The Relation of Adiposity to Blood Pressure and Development of Hypertension. Ann Intern Med. 1967;67(1):48. doi: https://doi.org/10.7326/0003-4819-67-1-48

314

315

Bogers RP. Association of Overweight With Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol Levels: A Meta-analysis of 21 Cohort Studies Including More Than 300 000 Persons. Arch Intern Med. 2007;167(16):1720. doi: https://doi.org/10.1001/archinte.167.16.1720

316

Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: A meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4761-4768. doi: https://doi.org/10.1016/j.ijcard.2013.07.230

317

318

Harrington M, Gibson S, Cottrell RC. A review and meta-analysis of the effect of weight loss on all-cause mortality risk. Nutr Res Rev. 2009;22(1):93-108. doi: https://doi.org/10.1017/S0954422409990035

319

Saneei P, Salehi-Abargouei A, Esmaillzadeh A, Azadbakht L. Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: A systematic review and meta-analysis on randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24(12):1253-1261. doi: https://doi.org/10.1016/j.numecd.2014.06.008

320

He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and metaanalysis of randomised trials. BMJ. 2013;346(apr03 3):f1325-f1325. doi: https://doi.org/10.1136/bmj.f1325

321

Neter JE, Stam BE, Kok FJ, et al. Influence of Weight Reduction on Blood Pressure. Hypertension. 2003;42(5):878-884. doi: https://doi.org/10.1161/01.HYP.0000094221.86888.AE

322

323

Kim H, Caulfield LE, Rebholz CM. Healthy Plant-Based Diets Are Associated with Lower Risk of All-Cause Mortality in US Adults. J Nutr. 2018;148(4):624-631. doi: https://doi.org/10.1093/jn/nxy019

324

Satija A, Bhupathiraju SN, Spiegelman D, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J Am Coll Cardiol. 2017;70(4):411-422. doi: https://doi.org/10.1016/j.jacc.2017.05.047

325

Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Association of Changes in Diet Quality with Total and CauseSpecific Mortality. N Engl J Med. 2017;377(2):143-153. doi: https://doi.org/10.1056/NEJMoa1613502

326

Whalen KA, Judd S, McCullough ML, Flanders WD, Hartman TJ, Bostick RM. Paleolithic and Mediterranean Diet Pattern Scores Are Inversely Associated with All-Cause and CauseSpecific Mortality in Adults. J Nutr. 2017;147(4):612-620. doi: https://doi.org/10.3945/jn.116.241919

327

Bao Y, Han J, Hu FB, et al. Association of Nut Consumption with Total and Cause-Specific Mortality. N Engl J Med. 2013;369(21):2001-2011. doi: https://doi.org/10.1056/NEJMoa1307352

328

Bernstein AM, Sun Q, Hu FB, et al. Major Dietary Protein Sources and Risk of Coronary Heart Disease in Women. Circulation. 2010;122(9):876-883. doi: https://doi.org/10.1161/CIRCULATIONAHA.109.915165

329

Song M, Fung TT, Hu FB, et al. Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality. JAMA Intern Med. 2016;176(10):1453. doi: https://doi.org/10.1001/jamainternmed.2016.4182

330

Tharrey M, Mariotti F, Mashchak A, et al. Patterns of plant and animal protein intake are strongly associated with cardiovascular mortality: the Adventist Health Study-2 cohort. Int J Epidemiol. 2018;47(5):1603-1612. doi: https://doi.org/10.1093/ije/dyy030

331

Martínez-González MA, Sánchez-Tainta A, Corella D, et al. A provegetarian food pattern and reduction in total mortality in the Prevención con Dieta Mediterránea (PREDIMED) study. Am J Clin Nutr. 2014;100(suppl_1):320S-328S. doi: https://doi.org/10.3945/ajcn.113.071431

332

Reedy J, Krebs-Smith SM, Miller PE, et al. Higher Diet Quality Is Associated with Decreased Risk of All-Cause, Cardiovascular Disease, and Cancer Mortality among Older Adults. J Nutr. 2014;144(6):881-889. doi: https://doi.org/10.3945/jn.113.189407

333

Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215-233. doi: https://doi.org/10.1097/01.hjh.0000199800.72563.26

334

Mente A, de Koning L, Shannon HS, Anand SS. A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease. Arch Intern Med. 2009;169(7):659. doi: https://doi.org/10.1001/archinternmed.2009.38

335

Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189-1196. doi: https://doi.org/10.3945/ajcn.2010.29673

336

Wang DD, Li Y, Chiuve SE, et al. Association of Specific Dietary Fats With Total and Cause-Specific Mortality. JAMA Intern Med. 016;176(8):1134. doi: https://doi.org/10.1001/jamainternmed.2016.2417

337

Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390(10107):2050-2062. doi: https://doi.org/10.1016/S0140-6736(17)32252-3

338

Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885. doi: https://doi.org/10.1136/bmj.39147.604896.55

339

Micha R, Peñalvo JL, Cudhea F, et al. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA. 2017;317(9):912. doi: https://doi.org/10.1001/jama.2017.0947

340

Yang Q, Zhang Z, Gregg EW, et al. Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults. JAMA Intern Med. 2014;174(4):516. doi: https://doi.org/10.1001/jamainternmed.2013.13563

341

Kiage JN, Merrill PD, Robinson CJ, et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr. 2013;97(5):1121-1128. doi: https://doi.org/10.3945/ajcn.112.049064

342

Löfvenborg JE, Andersson T, Carlsson P-O, et al. Sweetened beverage intake and risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Eur J Endocrinol. 2016;175(6):605-614. doi: https://doi.org/10.1530/EJE-16-0376

343

Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. N Engl J Med. 2001;344(1):3-10. doi: https://doi.org/10.1056/NEJM200101043440101

344

Johnson RK, Lichtenstein AH, Anderson CAM, et al. Low-Calorie Sweetened Beverages and Cardiometabolic Health: A Science Advisory From the American Heart Association. Circulation. 2018;138(9). doi: https://doi.org/10.1161/CIR.0000000000000569

345

Shikany JM, Safford MM, Newby PK, et al. Southern Dietary Pattern Is Associated With Hazard of Acute Coronary Heart Disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circulation. 2015;132(9):804-814. doi: https://doi.org/10.1161/CIRCULATIONAHA.114.014421

346

Seidelmann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Heal. 2018;3(9):e419-e428. doi: https://doi.org/10.1016/S2468-2667(18)30135-X

347

Trichopoulou A, Psaltopoulou T, Orfanos P, et al. Lowcarbohydrate–high-protein diet and long-term survival in a general population cohort. Eur J Clin Nutr. 2007;61(5):575-581. doi: https://doi.org/10.1038/sj.ejcn.1602557

348

Noto H, Goto A, Tsujimoto T, Noda M. Low-Carbohydrate Diets and All-Cause Mortality: A Systematic Review and Meta-Analysis of Observational Studies. Manzoli L, ed. PLoS One. 2013;8(1):e55030. doi: https://doi.org/10.1371/journal.pone.0055030

349

Brandt EJ, Myerson R, Perraillon MC, Polonsky TS. Hospital Admissions for Myocardial Infarction and Stroke Before and After the TransFatty Acid Restrictions in New York. JAMA Cardiol. 2017;2(6):627. doi: https://doi.org/10.1001/jamacardio.2017.0491

350

Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol. 2009;5(6):335-344. doi: https://doi.org/10.1038/nrendo.2009.79

351

Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity. Circulation. 2016;133(2):187-225. doi: https://doi.org/10.1161/CIRCULATIONAHA.115.018585

352

Hansen D, Niebauer J, Cornelissen V, et al. Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group. Sport Med. 2018;48(8):1781-1797. doi: https://doi.org/10.1007/s40279-018-0930-4

353

354

Ricci C, Gaeta M, Rausa E, et al. Long-Term Effects of Bariatric Surgery on Type II Diabetes, Hypertension and Hyperlipidemia: A MetaAnalysis and Meta-Regression Study with 5-Year Follow-Up. Obes Surg. 2015;25(3):397-405. doi: https://doi.org/10.1007/s11695-014-1442-4

355

Ricci C, Gaeta M, Rausa E, et al. Early Impact of Bariatric Surgery on Type II Diabetes, Hypertension, and Hyperlipidemia: A Systematic Review, Meta-Analysis and Meta-Regression on 6,587 Patients. Obes Surg. 2014;24(4):522-528. doi: https://doi.org/10.1007/s11695-013-1121-x

356

Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery. JAMA. 2004;292(14):1724. doi: https://doi.org/10.1001/jama.292.14.1724

357

Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085):2226-2237. doi: https://doi.org/10.1016/S0140-6736(17)30754-7

358

Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25(2):83-92. doi: https://doi.org/10.3109/08037051.2015.1106750

359

Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37(12):955-964. doi: https://doi.org/10.1093/eurheartj/ehv633

360

SPRINT Research Group, et al. A Randomized Trial of Intensive versus Standard BloodPressure Control. N Engl J Med. 2015;373(22):2103-2116. doi: https://doi.org/10.1056/NEJMoa1511939

361

Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. (In Russ.). doi: https://doi.org/10.14341/DM221S1

362

Tsai W-C, Wu H-Y, Peng Y-S, et al. Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease. JAMA Intern Med. 2017;177(6):792. doi: https://doi.org/10.1001/jamainternmed.2017.0197

363

Jafar TH, Stark PC, Schmid CH, et al. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Ann Intern Med. 2003;139(4):244. doi: https://doi.org/10.7326/0003-4819-139-4-200308190-00006

364

Sim JJ, Shi J, Kovesdy CP, et al. Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population. J Am Coll Cardiol. 2014;64(6):588-597. doi: https://doi.org/10.1016/j.jacc.2014.04.065

365

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. J Hypertens. 2017;35(5):922-944. doi: https://doi.org/10.1097/HJH.0000000000001276

366

Owen JG, Reisin E. Anti-hypertensive Drug Treatment of Patients with and the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications. Curr Hypertens Rep. 2015;17(6):46. doi: https://doi.org/10.1007/s11906-015-0558-9

367

Tocci G, Paneni F, Palano F, et al. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A MetaAnalysis of Placebo-Controlled Clinical Trials. Am J Hypertens. 2011;24(5):582-590. doi: https://doi.org/10.1038/ajh.2011.8

368

Abuissa H, Jones PG, Marso SP, O’Keefe JH. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes. J Am Coll Cardiol. 2005;46(5):821-826. doi: https://doi.org/10.1016/j.jacc.2005.05.051

369

Yang Y, Wei R, Xing Y, et al. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients. Metabolism. 2013;62(12):1858-1866. doi: https://doi.org/10.1016/j.metabol.2013.08.008

370

Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30(6):487-496. doi: https://doi.org/10.1016/S1262-3636(07)70146-5

371

Andraws R, Brown DL. Effect of Inhibition of the Renin-Angiotensin System on Development of Type 2 Diabetes Mellitus (MetaAnalysis of Randomized Trials). Am J Cardiol. 2007;99(7):1006-1012. doi: https://doi.org/10.1016/j.amjcard.2006.10.068

372

Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995-1003. doi: https://doi.org/10.1016/S0140-6736(02)08089-3

373

Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031. doi: https://doi.org/10.1016/S0140-6736(04)16451-9

374

Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-781. doi: https://doi.org/10.1016/S0140-6736(03)14285-7

375

Califf RM, Boolell M, Haffner SM, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623-632. doi: https://doi.org/10.1016/j.ahj.2008.05.017

376

Takagi H, Niwa M, Mizuno Y, Goto S, Umemoto T. Telmisartan as a metabolic sartan: The first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013;7(3):229-235. doi: https://doi.org/10.1016/j.jash.2013.02.006

377

Alderman M, Aiyer KJ V. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 2004;20(3):369-379. doi: https://doi.org/10.1185/030079904125002982

378

Mychka VB, Chazova IE. Russian evidence-based medicine - MINOTAVR program: advantages of the retard form of indapamide in the treatment of metabolic syndrome. Consilium medicum. 2006;8(5):46-50. (In Russ.).

379

Zillich AJ, Garg J, Basu S, et al. Thiazide Diuretics, Potassium, and the Development of Diabetes. Hypertension. 2006;48(2):219-224. doi: https://doi.org/10.1161/01.HYP.0000231552.10054.aa

380

Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18(9):669-675. doi: https://doi.org/10.1038/sj.jhh.1001676

381

Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens. 2013;2013:1-9. doi: https://doi.org/10.1155/2013/541689

382

Chazova I. E., Mychka V. B. Novye vozmozhnosti v lechenii bol’nykh s metabolicheskim sindromom (rezul’taty issledovaniya ALMAZ) // Sistemnye gipertenzii. 2006;(2):14-17. (In Russ.).

383

Instructions for the medical use of the medicinal product for medical use Sibutramine. State Register of Medicines of the Ministry of Health of the Russian Federation. (In Russ.). Available at: https://grls.rosminzdrav.ru/grls.aspx

384

Instructions for the medical use of the medicinal product for medical use Liraglutide. State Register of Medicines of the Ministry of Health of the Russian Federation. (In Russ.). Available at: https://grls.rosminzdrav.ru/grls.aspx

385

Instructions for the medical use of the medicinal product for medical use Orlistat. State Register of Medicines of the Ministry of Health of the Russian Federation. (In Russ.). Available at: https://grls.rosminzdrav.ru/grls.aspx

386

Klop B, Elte J, Cabezas M. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. 2013;5(4):1218-1240. doi: https://doi.org/10.3390/nu5041218

387

Björnson E, Adiels M, Taskinen M-R, Borén J. Kinetics of plasma triglycerides in abdominal obesity. Curr Opin Lipidol. November 2016:1. doi: https://doi.org/10.1097/MOL.0000000000000375

388

Mandviwala T, Khalid U, Deswal A. Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker? Curr Atheroscler Rep. 2016;18(5):21. doi: https://doi.org/10.1007/s11883-016-0575-4

389

Feingold KR. Obesity and Dyslipidemia. [Updated 2020 Nov 2]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305895/

390

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi: https://doi.org/10.1093/eurheartj/ehx144

391

Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the Risk of Coronary Heart Disease. Circulation. 2007;115(4):450-458. doi: https://doi.org/10.1161/CIRCULATIONAHA.106.637793

392

Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceriderich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-1361. doi: https://doi.org/10.1093/eurheartj/ehr112

393

Fruchart J-C, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res. 2008;5(4):319-335. doi: https://doi.org/10.3132/dvdr.2008.046

394

Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi: https://doi.org/10.1016/S0140-6736(12)60312-2

395

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):623-632. doi: https://doi.org/10.1161/CIR.0000000000000678

396

397

Kim H, Caulfield LE, Garcia‐Larsen V, Steffen LM, Coresh J, Rebholz CM. Plant‐Based Diets Are Associated With a Lower Risk of Incident Cardiovascular Disease, Cardiovascular Disease Mortality, and All‐Cause Mortality in a General Population of Middle‐Aged Adults. J Am Heart Assoc. 2019;8(16). doi: https://doi.org/10.1161/JAHA.119.012865

398

399

400

401

402

Bao Y, Han J, Hu FB, et al. Association of Nut Consumption with Total and Cause-Specific Mortality. N Engl J Med. 2013;369(21):2001-2011. doi: https://doi.org/10.1056/NEJMoa1307352

403

Bernstein AM, Sun Q, Hu FB, Stampfer MJ, Manson JE, Willett WC. Major Dietary Protein Sources and Risk of Coronary Heart Disease in Women. Circulation. 2010;122(9):876-883. doi: https://doi.org/10.1161/CIRCULATIONAHA.109.915165

404

405

406

407

Mensink RP, Zock PL, Kester ADM, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a metaanalysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):1146-1155. doi: https://doi.org/10.1093/ajcn/77.5.1146

408

Schwingshackl L, Bogensberger B, Benčič A, et al. Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis. J Lipid Res. 2018;59(9):1771-1782. doi: https://doi.org/10.1194/jlr.P085522

409

Kastorini C-M, Milionis HJ, Esposito K, et al. The Effect of Mediterranean Diet on Metabolic Syndrome and its Components. J Am Coll Cardiol. 2011;57(11):1299-1313. doi: https://doi.org/10.1016/j.jacc.2010.09.073

410

Grundy SM, Stone NJ. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*. Ann Intern Med. 2019;170(11):779. doi: https://doi.org/10.7326/M19-0365

411

412

413

414

Wang DD, Li Y, Chiuve SE, et al. Association of Specific Dietary Fats With Total and CauseSpecific Mortality. JAMA Intern Med. 2016;176(8):1134. doi: https://doi.org/10.1001/jamainternmed.2016.2417

415

416

417

418

419

420

421

Yang Q, Zhang Z, Gregg EW, et al. Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults. JAMA Intern Med. 2014;174(4):516. doi: https://doi.org/10.1001/jamainternmed.2013.13563

422

423

424

425

Trichopoulou A, Psaltopoulou T, Orfanos P, Hsieh C-C, Trichopoulos D. Low-carbohydrate–high-protein diet and long-term survival in a general population cohort. Eur J Clin Nutr. 2007;61(5):575-581. doi: https://doi.org/10.1038/sj.ejcn.1602557

426

Noto H, Goto A, Tsujimoto T, Noda M. LowCarbohydrate Diets and All-Cause Mortality: A Systematic Review and Meta-Analysis of Observational Studies. Manzoli L, ed. PLoS One. 2013;8(1):e55030. doi: https://doi.org/10.1371/journal.pone.0055030

427

428

Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol. 2009;5(6):335-344. doi: https://doi.org/10.1038/nrendo.2009.79

429

Taskinen M-R, Söderlund S, Bogl LH, et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. J Intern Med. 2017;282(2):187-201. doi: https://doi.org/10.1111/joim.12632

430

431

He FJ, Li J, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. April 2013. doi: https://doi.org/10.1002/14651858.CD004937.pub2

432

Neter JE, Stam BE, Kok FJ, et al. Influence of Weight Reduction on Blood Pressure. Hypertension. 2003;42(5):878-884. doi: https://doi.org/10.1161/01.HYP.0000094221.86888.AE

433

Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319(7224):1523-1528. doi: https://doi.org/10.1136/bmj.319.7224.1523

434

Brien SE, Ronksley PE, Turner BJ, et al. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ. 2011;342(feb22 1):d636-d636. doi: https://doi.org/10.1136/bmj.d636

435

Griswold MG, Fullman N, Hawley C, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015-1035. doi: https://doi.org/10.1016/S0140-6736(18)31310-2

436

Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513-1523. doi: https://doi.org/10.1016/S0140-6736(18)30134-X

437

Huffman KM, Hawk VH, Henes ST, et al. Exercise effects on lipids in persons with varying dietary patterns—does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I. Am Heart J. 2012;164(1):117-124. doi: https://doi.org/10.1016/j.ahj.2012.04.014

438

Kraus WE, Powell KE, Haskell WL, et al. Physical Activity, AllCause and Cardiovascular Mortality, and Cardiovascular Disease. Med Sci Sport Exerc. 2019;51(6):1270-1281. doi: https://doi.org/10.1249/MSS.0000000000001939

439

Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020. doi: https://doi.org/10.1001/jama.2018.14854

440

Shaw KA, Gennat HC, O’Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. October 2006. doi: https://doi.org/10.1002/14651858.CD003817.pub3

441

Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69(4):632-646. doi: https://doi.org/10.1093/ajcn/69.4.632

442

Kraus WE, Houmard JA, Duscha BD, et al. Effects of the Amount and Intensity of Exercise on Plasma Lipoproteins. N Engl J Med. 2002;347(19):1483-1492. doi: https://doi.org/10.1056/NEJMoa020194

443

Kodama S. Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol. Arch Intern Med. 2007;167(10):999. doi: https://doi.org/10.1001/archinte.167.10.999

444

Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: A meta-analysis of randomized controlled trials. Prev Med (Baltim). 2009;48(1):9-19. doi: https://doi.org/10.1016/j.ypmed.2008.10.010

445

Kelley GA, Kelley KS, Franklin B. Aerobic Exercise and Lipids and Lipoproteins in Patients With Cardiovascular Disease. J Cardiopulm Rehabil. 2006;26(3):131-139. doi: https://doi.org/10.1097/00008483-200605000-00002

446

Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery. JAMA. 2004;292(14):1724. doi: https://doi.org/10.1001/jama.292.14.1724

447

Heffron SP, Parikh A, Volodarskiy A, et al. Changes in Lipid Profile of Obese Patients Following Contemporary Bariatric Surgery: A Meta-Analysis. Am J Med. 2016;129(9):952-959. doi: https://doi.org/10.1016/j.amjmed.2016.02.004

448

Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi: https://doi.org/10.1016/S0140-6736(10)61350-5

449

Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: metaanalysis of individual data from 174 000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-1405. doi: https://doi.org/10.1016/S0140-6736(14)61368-4

450

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi: https://doi.org/10.1056/NEJMoa1801174

451

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi: https://doi.org/10.1056/NEJMoa1615664

452

Cannon CP, Steinberg BA, Murphy SA, et al. Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. J Am Coll Cardiol. 2006;48(3):438-445. doi: https://doi.org/10.1016/j.jacc.2006.04.070

453

Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statins in Stroke Prevention and Carotid Atherosclerosis. Stroke. 2004;35(12):2902-2909. doi: https://doi.org/10.1161/01.STR.0000147965.52712.fa

454

Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125. doi: https://doi.org/10.1016/S0140-6736(08)60104-X

455

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278. doi: https://doi.org/10.1016/S0140-6736(05)67394-1

456

Wang J, Chen D, Li D-B, Yu X, Shi G-B. Comparison of the efficacy and safety of intensive-dose and standard-dose statin treatment for stroke prevention. Medicine (Baltimore). 2016;95(39):e4950. doi: https://doi.org/10.1097/MD.0000000000004950

457

Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265(5):568-580. doi: https://doi.org/10.1111/j.1365-2796.2008.02062.x

458

Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251-261. doi: https://doi.org/10.1016/j.atherosclerosis.2012.02.016

459

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi: https://doi.org/10.1093/eurheartj/ehz455

460

Diagnostika i korrektsiya narushenii lipidnogo obmena s tsel’yu profilaktiki i lecheniya ateroskleroza. Rossiiskie rekomendatsii, VII peresmotr. Ateroskleroz i Dislipidemii. 2020;38(1):7-42. (in Russ.). doi: https://doi.org/10.34687/2219-8202.JAD.2020.01.0002

461

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: https://doi.org/10.1056/NEJMoa1812792

462

Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5):385-391. doi: https://doi.org/10.1097/00043798-199710000-00011

463

Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019;140(12):111-188. doi: https://doi.org/10.1161/CIR.0000000000000709

464

Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol. 2016;10(4):905-914. doi: https://doi.org/10.1016/j.jacl.2016.03.008

465

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861. doi: https://doi.org/10.1016/S0140-6736(05)67667-2

466

Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. September 2019:l5125. doi: https://doi.org/10.1136/bmj.l5125

467

Kenchaiah S, Evans JC, Levy D, et al. Obesity and the Risk of Heart Failure. N Engl J Med. 2002;347(5):305-313. doi: https://doi.org/10.1056/NEJMoa020245

468

Pandey A, LaMonte M, Klein L, et al. Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. J Am Coll Cardiol. 2017;69(9):1129-1142. doi: https://doi.org/10.1016/j.jacc.2016.11.081

469

Elagizi A, Kachur S, Lavie CJ, et al. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis. 2018;61(2):142-150. doi: https://doi.org/10.1016/j.pcad.2018.07.003

470

Obokata M, Reddy YNV, Pislaru S V., Melenovsky V, Borlaug BA. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6-19. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.026807

471

Packer M. The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. Eur J Heart Fail. 2019;21(2):156-162. doi: https://doi.org/10.1002/ejhf.1377

472

Padwal R, McAlister FA, McMurray JJ V, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes. 2014;38(8):1110-1114. doi: https://doi.org/10.1038/ijo.2013.203

473

Carbone S, Canada JM, Buckley LF, et al. Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2016;68(22):2487-2488. doi: https://doi.org/10.1016/j.jacc.2016.08.072

474

Ross R, Blair SN, Arena R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation. 2016;134(24). doi: https://doi.org/10.1161/CIR.0000000000000461

475

Miller SL, Wolfe RR. The danger of weight loss in the elderly. J Nutr Heal Aging. 2008;12(7):487-491. doi: https://doi.org/10.1007/BF02982710

476

Carbone S, Canada JM, Buckley LF, et al. Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction. JACC Basic to Transl Sci. 2017;2(5):513-525. doi: https://doi.org/10.1016/j.jacbts.2017.06.009

477

Pack QR, Rodriguez-Escudero JP, Thomas RJ, et al. The Prognostic Importance of Weight Loss in Coronary Artery Disease: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2014;89(10):1368-1377. doi: https://doi.org/10.1016/j.mayocp.2014.04.033

478

Poirier P, Giles TD, Bray GA, et al. Obesity and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2006;26(5):968-976. doi: https://doi.org/10.1161/01.ATV.0000216787.85457.f3

479

Kenchaiah S, Evans JC, Levy D, et al. Obesity and the Risk of Heart Failure. N Engl J Med. 2002;347(5):305-313. doi: https://doi.org/10.1056/NEJMoa020245

480

Curtis JP, Selter JG, Wang Y, et al. The Obesity Paradox. Arch Intern Med. 2005;165(1):55. doi: https://doi.org/10.1001/archinte.165.1.55

481

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62(16):e147-e239. doi: https://doi.org/10.1016/j.jacc.2013.05.019

482

McMurray JJ V., Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur Heart J. 2012;33(14):1787-1847. doi: https://doi.org/10.1093/eurheartj/ehs104

483

Williamson DF. Weight loss and mortality in persons with type-2 diabetes mellitus: a review of the epidemiological evidence. Exp Clin Endocrinol Diabetes. 2009;106(S 02):14-21. doi: https://doi.org/10.1055/s-0029-1212031

484

Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional Weight Loss and All-Cause Mortality: A Meta-Analysis of Randomized Clinical Trials. Wu W-CH, ed. PLoS One. 2015;10(3):e0121993. doi: https://doi.org/10.1371/journal.pone.0121993

485

Kenchaiah S, Evans JC, Levy D, et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med. 2013;369(2):145-154. doi: https://doi.org/10.1056/NEJMoa1212914

486

van Dijk SB, Takken T, Prinsen EC, Wittink H. Different anthropometric adiposity measures and their association with cardiovascular disease risk factors: a meta-analysis. Netherlands Hear J. 2012;20(5):208-218. doi: https://doi.org/10.1007/s12471-011-0237-7

487

Lazo M, Clark J. The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective. Semin Liver Dis. 2008;28(04):339-350. doi: https://doi.org/10.1055/s-0028-1091978

488

Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11(1):50-55. doi: https://doi.org/10.1007/s11894-009-0008-4

489

Stefan N, Kantartzis K, Häring H-U. Causes and Metabolic Consequences of Fatty Liver. Endocr Rev. 2008;29(7):939-960. doi: https://doi.org/10.1210/er.2008-0009

490

Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2009;11(6):430-445. doi: https://doi.org/10.1111/j.1467-789X.2009.00657.x

491

Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103(2):71-83. doi: https://doi.org/10.1093/qjmed/hcp158

492

Nafisa A, Gray SG, Cao Y, et al. Endothelial function and dysfunction: Impact of metformin. Pharmacol Ther. 2018;192(1):150-162. doi: https://doi.org/10.1016/j.pharmthera.2018.07.007

493

Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clin Liver Dis. 2007;11(1):1-16. doi: https://doi.org/10.1016/j.cld.2007.02.009

494

Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113-119. doi: https://doi.org/10.1111/j.1478-3231.2008.01718.x

495

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: https://doi.org/10.1002/hep.28431

496

Nafisa A, Gray SG, Cao Y, et al. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004

497

Chalasani N, Younossi Z, Lavine JE, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107(6):811-826. doi: https://doi.org/10.1038/ajg.2012.128

498

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi: https://doi.org/10.1002/hep.29367

499

Karlas T, Petroff D, Sasso M, et al. Individual patient data metaanalysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi: https://doi.org/10.1016/j.jhep.2016.12.022

500

Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e2. doi: https://doi.org/10.1016/j.cgh.2018.04.043

501

Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(6):1717-1730. doi: https://doi.org/10.1053/j.gastro.2019.01.042

502

Katsagoni CN, Georgoulis M, Papatheodoridis G V., Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119-132. doi: https://doi.org/10.1016/j.metabol.2016.12.006

503

Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-846. doi: https://doi.org/10.1016/j.jhep.2017.05.016

504

Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344(jan10 2):d7771-d7771. doi: https://doi.org/10.1136/bmj.d7771

505

Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebocontrolled phase 2 study. Lancet. 2016;387(10019):679-690. doi: https://doi.org/10.1016/S0140-6736(15)00803-X

506

Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79-104. doi: https://doi.org/10.1002/hep.23623

507

Li Y, Liu L, Wang B, et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Reports. 2013;1(1):57-64. doi: https://doi.org/10.3892/br.2012.18

508

Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393-403. doi: https://doi.org/10.1056/NEJMoa012512

509

Doycheva I, Loomba R. Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD). Adv Ther. 2014;31(1):30-43. doi: https://doi.org/10.1007/s12325-013-0084-6

510

Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes. 2010;34(8):1255-1264. doi: https://doi.org/10.1038/ijo.2010.40

511

Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20(1):23-28. doi: https://doi.org/10.1111/j.1365-2036.2004.02025.x

512

Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;29(2):172-182. doi: https://doi.org/10.1111/j.1365-2036.2008.03869.x

513

de Oliveira CPMS, Stefano JT, de Siqueira ERF, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with nonalcoholic steatohepatitis. Hepatol Res. 2007;38:159-165. doi: https://doi.org/10.1111/j.1872-034X.2007.00215.x

514

Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol. 2009;2(3):157-163. doi: https://doi.org/10.1177/1756283X09105462

515

Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19(5):537-544. doi: https://doi.org/10.1111/j.1365-2036.2004.01888.x

516

Haukeland JW, Konopski Z, Eggesbø HB, et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853-860. doi: https://doi.org/10.1080/00365520902845268

517

Sanyal AJ, Chalasani N, Kowdley K V., et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. doi: https://doi.org/10.1056/NEJMoa0907929

518

Sato K, Gosho M, Yamamoto T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Nutrition. 2015;31(7-8):923-930. doi: https://doi.org/10.1016/j.nut.2014.11.018

519

Xu R, Tao A, Zhang S, et al. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8(3):3924-3934.

520

Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality. Ann Intern Med. 2005;142(1):37. doi: https://doi.org/10.7326/0003-4819-142-1-200501040-00110

521

522

Lassailly G, Caiazzo R, Buob D, et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015;149(2):379-388. doi: https://doi.org/10.1053/j.gastro.2015.04.014

523

Bower G, Toma T, Harling L, et al. Bariatric Surgery and NonAlcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology. Obes Surg. 2015;25(12):2280-2289. doi: https://doi.org/10.1007/s11695-015-1691-x

524

Volkert D, Beck AM, Cederholm T, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr. 2019;38(1):10-47. doi: https://doi.org/10.1016/j.clnu.2018.05.024

525

Gallus S, Lugo A, Murisic B, Bosetti C, Boffetta P, La Vecchia C. Overweight and obesity in 16 European countries. Eur J Nutr. 2015;54(5):679-689. doi: https://doi.org/10.1007/s00394-014-0746-4

526

Porter Starr K, McDonald S, Weidner J, Bales C. Challenges in the Management of Geriatric Obesity in High Risk Populations. Nutrients. 2016;8(5):262. doi: https://doi.org/10.3390/nu8050262

527

Kuk JL, Ardern CI. Influence of Age on the Association Between Various Measures of Obesity and All-Cause Mortality. J Am Geriatr Soc. 2009;57(11):2077-2084. doi: https://doi.org/10.1111/j.1532-5415.2009.02486.x

528

Roubenoff R. Sarcopenic Obesity: The Confluence of Two Epidemics. Obes Res. 2004;12(6):887-888. doi: https://doi.org/10.1038/oby.2004.107

529

Stessman J, Jacobs JM, Ein-Mor E, Bursztyn M. Normal Body Mass Index Rather than Obesity Predicts Greater Mortality in Elderly People: The Jerusalem Longitudinal Study. J Am Geriatr Soc. 2009;57(12):2232-2238. doi: https://doi.org/10.1111/j.1532-5415.2009.02567.x

530

Schott AM, Cormier C, Hans D, et al. How Hip and Whole-Body Bone Mineral Density Predict Hip Fracture in Elderly Women: The EPIDOS Prospective Study. Osteoporos Int. 1998;8(3):247-254. doi: https://doi.org/10.1007/s001980050061

531

WHO Consultation on Obesity (1997: Geneva, Switzerland), World Health Organization. Division of Noncommunicable Diseases & World Health Organization. Programme of Nutrition, Family and Reproductive Health. (1998). Obesity: preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/63854

532

533

Kriaucioniene V, Petkeviciene J, Raskiliene A. Nutrition and physical activity counselling by general practitioners in Lithuania, 2000–2014. BMC Fam Pract. 2019;20(1):125. doi: https://doi.org/10.1186/s12875-019-1022-8

534

Schultz TJ, Roupas P, Wiechula R, et al. Nutritional interventions for optimizing healthy body composition in older adults in the community. JBI Database Syst Rev Implement Reports. 2016;14(8):257-308. doi: https://doi.org/10.11124/JBISRIR-2016-003063

535

Normandin E, Houston DK, Nicklas BJ. Caloric Restriction for Treatment of Geriatric Obesity: Do the Benefits Outweigh the Risks? Curr Nutr Rep. 2015;4(2):143-155. doi: https://doi.org/10.1007/s13668-015-0123-9

536

Mathus-Vliegen EMH, Basdevant A, Finer N, et al. Prevalence, Pathophysiology, Health Consequences and Treatment Options of Obesity in the Elderly: A Guideline. Obes Facts. 2012;5(3):460-483. doi: https://doi.org/10.1159/000341193

537

Goisser S, Kemmler W, Porzel S, et al. Sarcopenic obesity and complex interventions with nutrition and exercise in communitydwelling older persons – A narrative review. Clin Interv Aging. 2015. doi: https://doi.org/10.2147/CIA.S82454

538

539

540

541

Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693-700. doi: https://doi.org/10.1097/MCO.0b013e328312c37d

542

Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1-203. doi: https://doi.org/10.4158/EP161365.GL

543

Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity. 2014;22(S2):S41-S410. doi: https://doi.org/10.1002/oby.20660

544

Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in Older Adults: Technical Review and Position Statement of the American Society for Nutrition and NAASO, The Obesity Society. Obes Res. 2005;13(11):1849-1863. doi: https://doi.org/10.1038/oby.2005.228

545

Visvanathan R, Haywood C, Piantadosi C, Appleton S. Australian and New Zealand Society for Geriatric Medicine. Australas J Ageing. 2012;31(4):261-267. doi: https://doi.org/10.1111/j.1741-6612.2012.00652.x

546

Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta- analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776-786. doi: https://doi.org/10.1016/S0140-6736(16)30175-1

547

Winter JE, MacInnis RJ, Wattanapenpaiboon N, Nowson CA. BMI and all-cause mortality in older adults: a meta-analysis. Am J Clin Nutr. 2014;99(4):875-890. doi: https://doi.org/10.3945/ajcn.113.068122

548

Flegal KM, Kit BK, Orpana H, Graubard BI. Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories. JAMA. 2013;309(1):71. doi: https://doi.org/10.1001/jama.2012.113905

549

Cetin DC, Nasr G. Obesity in the elderly: More complicated than you think. Cleve Clin J Med. 2014;81(1):51-61. doi: https://doi.org/10.3949/ccjm.81a.12165

550

Parr EB, Coffey VG, Hawley JA. ‘Sarcobesity’: A metabolic conundrum. Maturitas. 2013;74(2):109-113. doi: https://doi.org/10.1016/j.maturitas.2012.10.014

551

Volpe SL, Sukumar D, Milliron B-J. Obesity Prevention in Older Adults. Curr Obes Rep. 2016;5(2):166-175. doi: https://doi.org/10.1007/s13679-016-0213-z

552

DiMilia PR, Mittman AC, Batsis JA. Benefit-to-Risk Balance of Weight Loss Interventions in Older Adults with Obesity. Curr Diab Rep. 2019;19(11):114. doi: https://doi.org/10.1007/s11892-019-1249-8

553

Batsis JA, Zagaria AB. Addressing Obesity in Aging Patients. Med Clin North Am. 2018;102(1):65-85. doi: https://doi.org/10.1016/j.mcna.2017.08.007

554

Fan H, Li X, Zheng L, et al. Abdominal obesity is strongly associated with Cardiovascular Disease and its Risk Factors in Elderly and very Elderly Community-dwelling Chinese. Sci Rep. 2016;6(1):21521. doi: https://doi.org/10.1038/srep21521

555

Tussing-Humphreys L, Lamar M, Blumenthal JA, et al. Building research in diet and cognition: The BRIDGE randomized controlled trial. Contemp Clin Trials. 2017;59:87-97. doi: https://doi.org/10.1016/j.cct.2017.06.003

556

Leavy J, Clifton P, Keogh J. The Role of Choice in Weight Loss Strategies: A Systematic Review and Meta-Analysis. Nutrients. 2018;10(9):1136. doi: https://doi.org/10.3390/nu10091136

557

Colpani V, Baena CP, Jaspers L, et al. Lifestyle factors, cardiovascular disease and all-cause mortality in middle-aged and elderly women: a systematic review and meta-analysis. Eur J Epidemiol. 2018;33(9):831-845. doi: https://doi.org/10.1007/s10654-018-0374-z

558

Gill LE, Bartels SJ, Batsis JA. Weight Management in Older Adults. Curr Obes Rep. 2015;4(3):379-388. doi: https://doi.org/10.1007/s13679-015-0161-z

559

Wojzischke J, Diekmann R, Bauer JM. Adipositas im Alter und ihre Bedeutung für Funktionalität und Frailty. Z Gerontol Geriatr. 2016;49(7):573-580. doi: https://doi.org/10.1007/s00391-016-1133-y

560

Ard JD, Gower B, Hunter G, et al. Effects of Calorie Restriction in Obese Older Adults: The CROSSROADS Randomized Controlled Trial. Journals Gerontol Ser A Biol Sci Med Sci. 2017;73(1):73-80. doi: https://doi.org/10.1093/gerona/glw237

561

Haas MC, Bodner E V., Brown CJ, et al. Calorie Restriction in Overweight Seniors: Response of Older Adults to a Dieting Study: The CROSSROADS Randomized Controlled Clinical Trial. J Nutr Gerontol Geriatr. 2014;33(4):376-400. doi: https://doi.org/10.1080/21551197.2014.965993

562

Mathus-Vliegen L, Toouli J, Fried M, et al. World Gastroenterology Organisation Global Guidelines on Obesity. J Clin Gastroenterol. 2012;46(7):555-561. doi: https://doi.org/10.1097/MCG.0b013e318259bd04

563

Zeanandin G, Molato O, Le Duff F, et al. Impact of restrictive diets on the risk of undernutrition in a free-living elderly population. Clin Nutr. 2012;31(1):69-73. doi: https://doi.org/10.1016/j.clnu.2011.08.007

564

Coker RH, Wolfe RR. Weight Loss Strategies in the Elderly: A Clinical Conundrum. Obesity. 2018;26(1):22-28. doi: https://doi.org/10.1002/oby.21961

565

Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. N Engl J Med. 2017;376(20):1943-1955. doi: https://doi.org/10.1056/NEJMoa1616338

566

Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. N Engl J Med. 2017;376(20):1943-1955. doi: https://doi.org/10.1056/NEJMoa1616338

567

Villareal DT, Chode S, Parimi N, et al. Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults. N Engl J Med. 2011;364(13):1218-1229. doi: https://doi.org/10.1056/NEJMoa1008234

568

Frimel TN, Sinacore DR, Villareal DT. Exercise Attenuates the Weight-Loss-Induced Reduction in Muscle Mass in Frail Obese Older Adults. Med Sci Sport Exerc. 2008;40(7):1213-1219. doi: https://doi.org/10.1249/MSS.0b013e31816a85ce

569

Avila JJ, Gutierres JA, Sheehy ME, et al. Effect of moderate intensity resistance training during weight loss on body composition and physical performance in overweight older adults. Eur J Appl Physiol. 2010;109(3):517-525. doi: https://doi.org/10.1007/s00421-010-1387-9

570

Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and Exercise Interventions Reduce Intrahepatic Fat Content and Improve Insulin Sensitivity in Obese Older Adults. Obesity. 2009;17(12):2162-2168. doi: https://doi.org/10.1038/oby.2009.126

571

Messier SP, Mihalko SL, Legault C, et al. Effects of Intensive Diet and Exercise on Knee Joint Loads, Inflammation, and Clinical Outcomes Among Overweight and Obese Adults With Knee Osteoarthritis. JAMA. 2013;310(12):1263. doi: https://doi.org/10.1001/jama.2013.277669

572

Chomentowski P, Dube JJ, Amati F, et al. Moderate Exercise Attenuates the Loss of Skeletal Muscle Mass That Occurs With Intentional Caloric Restriction-Induced Weight Loss in Older, Overweight to Obese Adults. Journals Gerontol Ser A Biol Sci Med Sci. 2009;64A(5):575-580. doi: https://doi.org/10.1093/gerona/glp007

573

Campbell WW, Haub MD, Wolfe RR, et al. Resistance Training Preserves Fat-free Mass Without Impacting Changes in Protein Metabolism After Weight Loss in Older Women. Obesity. 2009;17(7):1332-1339. doi: https://doi.org/10.1038/oby.2009.2

574

Dunstan DW, Daly RM, Owen N, et al. High-Intensity Resistance Training Improves Glycemic Control in Older Patients With Type 2 Diabetes. Diabetes Care. 2002;25(10):1729-1736. doi: https://doi.org/10.2337/diacare.25.10.1729

575

Kitzman DW, Brubaker P, Morgan T, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 2016;315(1):36. doi: https://doi.org/10.1001/jama.2015.17346

576

Amati F, Dubé JJ, Shay C, Goodpaster BH. Separate and combined effects of exercise training and weight loss on exercise efficiency and substrate oxidation. J Appl Physiol. 2008;105(3):825-831. doi: https://doi.org/10.1152/japplphysiol.90384.2008

577

Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: The arthritis, diet, and activity promotion trial. Arthritis Rheum. 2004;50(5):1501-1510. doi: https://doi.org/10.1002/art.20256

578

Rejeski WJ, Ambrosius WT, Burdette JH, Walkup MP, Marsh AP. Community Weight Loss to Combat Obesity and Disability in At-Risk Older Adults. Journals Gerontol Ser A Biol Sci Med Sci. 2017;72(11):1547e53. doi: https://doi.org/10.1093/gerona/glw252

579

Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, et al. Exercise and Physical Activity for Older Adults. Med Sci Sport Exerc. 2009;41(7):1510-1530. doi: https://doi.org/10.1249/MSS.0b013e3181a0c95c

580

Moore G, Durstine JL, Painter P, Medicine AcoS. ACSM’s exercise management for persons with chronic diseases and disabilities. 4E: Human Kinetics; 2016.

581

Janssen I, Mark AE. Elevated body mass index and mortality risk in the elderly. Obes Rev. 2007;8(1):41-59. doi: https://doi.org/10.1111/j.1467-789X.2006.00248.x

582

Adams KF, Schatzkin A, Harris TB, et al. Overweight, Obesity, and Mortality in a Large Prospective Cohort of Persons 50 to 71 Years Old. N Engl J Med. 2006;355(8):763-778. doi: https://doi.org/10.1056/NEJMoa055643

583

Carbone S, Dixon DL. Selecting appropriate weight loss pharmacotherapies in older adults to reduce cardiovascular risk. Expert Opin Pharmacother. 2018;19(13):1399-1402. doi: https://doi.org/10.1080/14656566.2018.1511704

584

Baumgartner RN. Body Composition in Healthy Aging. Ann N Y Acad Sci. 2006;904(1):437-448. doi: https://doi.org/10.1111/j.1749-6632.2000.tb06498.x

585

State Register of Medicines of the Ministry of Health of the Russian Federation. (In Russ.). Available at: https://grls.rosminzdrav.ru/grls.aspx

586

Lavie CJ, Sharma A, Alpert MA, et al. Update on Obesity and Obesity Paradox in Heart Failure. Prog Cardiovasc Dis. 2016;58(4):393-400. doi: https://doi.org/10.1016/j.pcad.2015.12.003

587

Carbone S, Popovic D, Lavie CJ, Arena R. Obesity, body composition and cardiorespiratory fitness in heart failure with preserved ejection fraction. Future Cardiol. 2017;13(5):451-463. doi: https://doi.org/10.2217/fca-2017-0023

588

Carbone S, Lavie CJ, Arena R. Obesity and Heart Failure: Focus on the Obesity Paradox. Mayo Clin Proc. 2017;92(2):266-279. doi: https://doi.org/10.1016/j.mayocp.2016.11.001

589

Lavie CJ, Carbone S, Agarwal MA. An obesity paradox with myocardial infarction in the elderly. Nutrition. 2018;46:122-123. doi: https://doi.org/10.1016/j.nut.2017.08.003

590

Wang ZJ, Zhou YJ, Galper BZ, et al. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart. 2015;101(20):1631-1638. doi: https://doi.org/10.1136/heartjnl-2014-307119

591

Keller K, Münzel T, Ostad MA. Sex-specific differences in mortality and the obesity paradox of patients with myocardial infarction ages >70 y. Nutrition. 2018;46(4):124-130. doi: https://doi.org/10.1016/j.nut.2017.09.004

592

Andersen KK, Olsen TS. The Obesity Paradox in Stroke: Lower Mortality and Lower Risk of Readmission for Recurrent Stroke in Obese Stroke Patients. Int J Stroke. 2015;10(1):99-104. doi: https://doi.org/10.1111/ijs.12016

593

Skolarus LE, Sanchez BN, Levine DA, et al. Association of Body Mass Index and Mortality After Acute Ischemic Stroke. Circ Cardiovasc Qual Outcomes. 2014;7(1):64-69. doi: https://doi.org/10.1161/CIRCOUTCOMES.113.000129

594

Zhao L, Du W, Zhao X, et al. Favorable Functional Recovery in Overweight Ischemic Stroke Survivors: Findings from the China National Stroke Registry. J Stroke Cerebrovasc Dis. 2014;23(3):e201-e206. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.10.002

595

Razinia T, Saver JL, Liebeskind DS, Ali LK, Buck B, Ovbiagele B. Body Mass Index and Hospital Discharge Outcomes After Ischemic Stroke. Arch Neurol. 2007;64(3):388. doi: https://doi.org/10.1001/archneur.64.3.388

596

Burke DT, Al-Adawi S, Bell RB, et al. Effect of Body Mass Index on Stroke Rehabilitation. Arch Phys Med Rehabil. 2014;95(6):1055-1059. doi: https://doi.org/10.1016/j.apmr.2014.01.019

597

Kim Y, Kim CK, Jung S, et al. Obesity-stroke paradox and initial neurological severity. J Neurol Neurosurg Psychiatry. 2015;86(7):743-747. doi: https://doi.org/10.1136/jnnp-2014-308664

598

Ovbiagele B, Bath PM, Cotton D, et al. Obesity and Recurrent Vascular Risk After a Recent Ischemic Stroke. Stroke. 2011;42(12):3397-3402. doi: https://doi.org/10.1161/STROKEAHA.111.624957

599

Andersen KK, Olsen TS. Body Mass Index and Stroke: Overweight and Obesity Less Often Associated with Stroke Recurrence. J Stroke Cerebrovasc Dis. 2013;22(8):e576-e581. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.06.031

600

Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 1999;55(4):1560-1567. doi: https://doi.org/10.1046/j.1523-1755.1999.00389.x

601

Glanton CW, Hypolite IO, Hshieh PB, et al. Factors Associated with Improved Short Term Survival in Obese End Stage Renal Disease Patients. Ann Epidemiol. 2003;13(2):136-143. doi: https://doi.org/10.1016/S1047-2797(02)00251-X

602

Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: Analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int. 2004;65(2):597-605. doi: https://doi.org/10.1111/j.1523-1755.2004.00385.x

603

Stack AG, Murthy BVR, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States. Kidney Int. 2004;65(6):2398-2408. doi: https://doi.org/10.1111/j.1523-1755.2004.00654.x

604

de Mutsert R, Grootendorst DC, Boeschoten EW, et al. Is Obesity Associated with a Survival Advantage in Patients Starting Peritoneal Dialysis? In: Peritoneal Dialysis - From Basic Concepts to Clinical Excellence. Basel: KARGER; 2009:124-131. doi: https://doi.org/10.1159/000223790

605

Zitt E, Fischer A, Lhotta K, Concin H, Nagel G. Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort. Sci Rep. 2020;10(1):7578. doi: https://doi.org/10.1038/s41598-020-64587-z

606

Maynard JW, McAdams DeMarco MA, Baer AN, et al. Incident Gout in Women and Association with Obesity in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Med. 2012;125(7):717.e9-717.e17. doi: https://doi.org/10.1016/j.amjmed.2011.11.018

607

Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Stu. Lancet. 2018;392(10159):1923-1994. doi: https://doi.org/10.1016/S0140-6736(18)32225-6

608

Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345-1422. doi: https://doi.org/10.1016/S0140-6736(17)32366-8

609

Chen J-H, Pan W-H, Hsu C-C, et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: A prospective study. Arthritis Care Res (Hoboken). 2013;65(1):133-140. doi: https://doi.org/10.1002/acr.21824

610

Juraschek SP, Miller ER, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007-2010. Arthritis Care Res (Hoboken). 2013;65(1):127-132. doi: https://doi.org/10.1002/acr.21791

611

Xia Y, Wu Q, Wang H, et al. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology. 2020;59(7):1529-1538. doi: https://doi.org/10.1093/rheumatology/kez476

612

Choi Y-J, Shin H-S, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Investig. 2014;94(10):1114-1125. doi: https://doi.org/10.1038/labinvest.2014.98

613

Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78(1):25-29. doi: https://doi.org/10.1210/jcem.78.1.8288709

614

Han T, Lan L, Qu R, et al. Temporal Relationship Between Hyperuricemia and Insulin Resistance and Its Impact on Future Risk of Hypertension. Hypertension. 2017;70(4):703-711. doi: https://doi.org/10.1161/HYPERTENSIONAHA.117.09508

615

Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. doi: https://doi.org/10.1002/art.22466

616

Hernández-Cuevas CB, Roque LH, Huerta-Sil G, et al. First Acute Gout Attacks Commonly Precede Features of the Metabolic Syndrome. JCR J Clin Rheumatol. 2009;15(2):65-67. doi: https://doi.org/10.1097/RHU.0b013e31819c0dba

617

White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomization analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-336. doi: https://doi.org/10.1016/S2213-8587(15)00386-1

618

Rahimi-Sakak F, Maroofi M, Rahmani J, et al. Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. BMC Cardiovasc Disord. 2019;19(1):218. doi: https://doi.org/10.1186/s12872-019-1215-z

619

Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189-192. doi: https://doi.org/10.1002/art.1780150209

620

Roddy E, Doherty M. Gout. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223. doi: https://doi.org/10.1186/ar3199

621

Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592-1600. doi: https://doi.org/10.1136/annrheumdis-2019-215933

622

Eliseev MS. Podagra. In: Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii. Moskva: GEOTAR-Media; 2017. S. 253-64. (In Russ.).

623

Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-1798. doi: https://doi.org/10.1136/annrheumdis-2015-208237

624

Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38. doi: https://doi.org/10.1136/annrheumdis-2019-215315

625

Eliseev MS, Vladimirov SA. Rasprostranennost’ i klinicheskie osobennosti podagry i bolezni deponirovaniya pirofosfata kal’tsiya u patsientov s ostrym artritom // Nauchno-prakticheskaya revmatologiya. 2015;(4):375-378. (In Russ.).

626

Dalbeth N, Schumacher HR, Fransen J, et al. Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care Res (Hoboken). 2016;68(12):1894-1898. doi: https://doi.org/10.1002/acr.22896

627

Christiansen SN, Østergaard M, Slot O, et al. Ultrasound for the diagnosis of gout—the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group. Rheumatology. 2021;60(1):239-249. doi: https://doi.org/10.1093/rheumatology/keaa366

628

Taylor WJ, Fransen J, Dalbeth N, et al. Performance of classification criteria for gout in early and established disease. Ann Rheum Dis. 2016;75(1):178-182. doi: https://doi.org/10.1136/annrheumdis-2014-206364

629

Gamala M, Jacobs JWG, Linn-Rasker SF, et al. The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis. Rheumatology. 2020;59(4):845-851. doi: https://doi.org/10.1093/rheumatology/kez391

630

Filippou G, Pascart T, Iagnocco A. Utility of Ultrasound and Dual Energy CT in Crystal Disease Diagnosis and Management. Curr Rheumatol Rep. 2020;22(5):15. doi: https://doi.org/10.1007/s11926-020-0890-1

631

Dedov II, Mel’nichenko GA, Shestakova M V., et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and Metabolism. 2018;15(1):53-70. (In Russ.). doi: https://doi.org/10.14341/omet2018153-70

632

Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology. 2010;49(12):2391-2399. doi: https://doi.org/10.1093/rheumatology/keq256

633

Barskova VG, Eliseev MS, Kudaeva FM, et al. Vliyanie metformina na techenie podagry i insulinorezistentnost’. Klinicheskaya meditsina. 2009;87(7):41-46. (In Russ.).

634

Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797-802. doi: https://doi.org/10.1136/annrheumdis-2013-203970

635

Dessein PH. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539-543. doi: https://doi.org/10.1136/ard.59.7.539

636

Zhou J, Wang Y, Lian F, et al. Physical exercises and weight loss in obese patients help to improve uric acid. Oncotarget. 2017;8(55):94893-94899. doi: https://doi.org/10.18632/oncotarget.22046

637

Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017;76(11):1870-1882. doi: https://doi.org/10.1136/annrheumdis-2017-211472

638

Santos FL, Esteves SS, da Costa Pereira A, Yancy Jr WS, Nunes JPL. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev. 2012;13(11):1048-1066. doi: https://doi.org/10.1111/j.1467-789X.2012.01021.x

639

Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. doi: https://doi.org/10.1002/acr.21772

640

Nguyen UDT, Zhang Y, Louie‐Gao Q, et al. Obesity Paradox in Recurrent Attacks of Gout in Observational Studies: Clarification and Remedy. Arthritis Care Res (Hoboken). 2017;69(4):561-566. doi: https://doi.org/10.1002/acr.22954

641

Bhole V, de Vera M, Rahman MM, et al. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum. 2010;62(4):1069-1076. doi: https://doi.org/10.1002/art.27338

642

Gaffo AL, Roseman JM, Jacobs DR, et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Ann Rheum Dis. 2010;69(11):1965-1970. doi: https://doi.org/10.1136/ard.2010.129429

643

Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277-1281. doi: https://doi.org/10.1016/S0140-6736(04)16000-5

644

Tumwesigye NM, Mutungi G, Bahendeka S, et al. Alcohol consumption, hypertension and obesity: Relationship patterns along different age groups in Uganda. Prev Med Reports. 2020;19:101141. doi: https://doi.org/10.1016/j.pmedr.2020.101141

645

Tsilas CS, de Souza RJ, Mejia SB, et al. Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Can Med Assoc J. 2017;189(20):E711-E720. doi: https://doi.org/10.1503/cmaj.160706

646

Stirpe F, Della Corte E, Bonetti E, et al. Fructose-induced hyperuricæmia. Lancet. 1970;296(7686):1310-1311. doi: https://doi.org/10.1016/S0140-6736(70)92269-5

647

Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-312. doi: https://doi.org/10.1136/bmj.39449.819271.BE

648

Choi HK, Willett W, Curhan G. Fructose-Rich Beverages and Risk of Gout in Women. JAMA. 2010;304(20):2270. doi: https://doi.org/10.1001/jama.2010.1638

649

Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283-289. doi: https://doi.org/10.1002/art.20761

650

Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis. 2012;71(9):1448-1453. doi: https://doi.org/10.1136/annrheumdis-2011-201215

651

Eliseev MS, Chikina MN, Kobel’kova IV, et al. Opredelenie gruppy riska po belkovomu i purinovomu disbalansu u vysokokvalifitsirovannykh sportsmenov v razlichnykh vidakh sporta. Lechebnaya fizkul’tura i sportivnaya meditsina.2019;152(2):6-13. (In Russ.).

652

Kullich W, Ulreich A, Klein G. Changes in uric acid and blood lipids in patients with asymptomatic hyperuricemia treated with diet therapy in a rehabilitation procedure. Rehabilitation (Stuttg). 1989;28(3):134-137.

653

Ellmann H, Bayat S, Araujo E, et al. Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits. Arthritis Rheumatol. 2020;72(1):150-156. doi: https://doi.org/10.1002/art.41063

654

Chen J-H, Wen CP, Wu SB, et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis. 2015;74(11):2034-2042. doi: https://doi.org/10.1136/annrheumdis-2014-205312

655

Park DY, Kim YS, Ryu SH, Jin YS. The association between sedentary behavior, physical activity and hyperuricemia. Vasc Health Risk Manag. 2019;15:291-299. doi: https://doi.org/10.2147/VHRM.S200278

656

Andersson C, Weeke P, Brendorp B, et al. Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab (Lond). 2009;6(1):42. doi: https://doi.org/10.1186/1743-7075-6-42

657

Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes, Obes Metab. 2002;4(1):49-55. doi: https://doi.org/10.1046/j.1463-1326.2002.00181.x

658

Tonneijck L, Muskiet MHA, Smits MM, et al. Effect of immediate and prolonged GLP‐1 receptor agonist administration on uric acid and kidney clearance: Post‐hoc analyses of four clinical trials. Diabetes, Obes Metab. 2018;20(5):1235-1245. doi: https://doi.org/10.1111/dom.13223

659

Vazirpanah N, Ottria A, van der Linden M, et al. mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019;78(5):663-671. doi: https://doi.org/10.1136/annrheumdis-2018-214656

660

Yu J, Lu H, Zhou J, et al. Oral prednisolone versus nonsteroidal anti-inflammatory drugs in the treatment of acute gout: a meta-analysis of randomized controlled trials. Inflammopharmacology. 2018;26(3):717-723. doi: https://doi.org/10.1007/s10787-018-0442-8

661

FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: https://doi.org/10.1002/acr.24180

662

Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-465. doi: https://doi.org/10.1517/14740338.2016.1140743

663

Fedorova AA, Barskova VG, Yakunina L, Nasonova VA. Short-term glucocorticoid administration in patients with protracted and chronic gout arthritis. Part 2 — comparison of different medication forms efficacy. Rheumatol Sci Pract. 2008;46(5):72-75. (In Russ.). doi: https://doi.org/10.14412/1995-4484-2008-418

664

Fedorova AA, Barskova VG, Yakunina IA, Nasonova VA. Short term administration of glucocorticoids in patients with protracted and chronic gout arthritis. Part III – frequency of adverse events. Rheumatol Sci Pract. 2009;62(2):38-42. (In Russ.). doi: https://doi.org/10.14412/1995-4484-2009-457

665

Tardif J-C, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505. doi: https://doi.org/10.1056/NEJMoa1912388

666

Solomon DH, Liu C-C, Kuo I-H, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-1679. doi: https://doi.org/10.1136/annrheumdis-2015-207984

667

Friedman JE, Dallal RM, Lord JL. Gouty attacks occur frequently in postoperative gastric bypass patients. Surg Obes Relat Dis. 2008;4(1):11-13. doi: https://doi.org/10.1016/j.soard.2007.09.012

668

Romero-Talamás H, Daigle CR, Aminian A, et al. The effect of bariatric surgery on gout: a comparative study. Surg Obes Relat Dis. 2014;10(6):1161-1165. doi: https://doi.org/10.1016/j.soard.2014.02.025

669

Yeo C, Kaushal S, Lim B, et al. Impact of bariatric surgery on serum uric acid levels and the incidence of gout—A meta‐analysis. Obes Rev. 2019;20(12):1759-1770. doi: https://doi.org/10.1111/obr.12940.

670

https://grls.rosminzdrav.ru/grls.aspx. Ссылка действительна на 10.08.2020 г.

671

Malm‐Erjefalt M, Ekblom M, Brondsted L, et al. A randomised, double‐blind, cross‐over trial investigating the effects of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes. 2008;56:434.

672

Jacobsen LV, Brondsted L, Vouis J, Zdaravkovic M. A randomized, double‐blind, cross‐over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug. Diabetes. 2008;57:2047‐PO.

673

Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther. 2011;28(8):650-660. doi: https://doi.org/10.1007/s12325-011-0044-y

674

Malm-Erjefält M, Ekblom M, Vouis J, et al. Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Mol Pharm. 2015;12(11):4166-4173. doi: https://doi.org/10.1021/acs.molpharmaceut.5b00278

675

Novo Nordisk A/S. Victoza: EU summary of product characteristics. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf.

676

Colman E, Fossler M. Reduction in Blood Cyclosporine Concentrations by Orlistat. N Engl J Med. 2000;342(15):1141-1142. doi: https://doi.org/10.1056/NEJM200004133421518

677

Nägele H, Petersen B, Bonacker U, Rödiger W. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. Eur J Clin Pharmacol. 1999;55(9):667-669. doi: https://doi.org/10.1007/s002280050690

678

Barbaro D, Orsini P, Pallini S, et al. Obesity in Transplant Patients: Case Report Showing Interference of Orlistat with Absorption of Cyclosporine and Review of Literature. Endocr Pract. 2002;8(2):124-126. doi: https://doi.org/10.4158/EP.8.2.124

679

Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic Evaluation of the Possible Interaction between Selected Concomitant Medications and Orlistat at Steady State in Healthy Subjects. J Clin Pharmacol. 2002;42(9):1011-1019. doi: https://doi.org/10.1177/0091270002042009008

680

Zhi J, Melia AT, Guerciolini R, et al. The Effect of Orlistat on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers. J Clin Pharmacol. 1996;36(7):659-666. doi: https://doi.org/10.1002/j.1552-4604.1996.tb04232.x

681

MacWalter RS, Fraser HW, Armstrong KM. Orlistat Enhances Warfarin Effect. Ann Pharmacother. 2003;37(4):510-512. doi: https://doi.org/10.1345/aph.1C122

682

Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers. J Clin Pharmacol. 2003;43(4):428-435. doi: https://doi.org/10.1177/0091270003252236

683

Holmbäck U, Forslund A, Grudén S, et al. Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obes Sci Pract. 2020;6(3):313-323. doi: https://doi.org/10.1002/osp4.405

684

Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat [letter]. Epilepsia. 2006;47(12):2207-2207. doi: https://doi.org/10.1111/j.1528-1167.2006.00945_1.x

685

Peleg R. Caution when using oral contraceptive pills with Orlistat [letter]. Isr Med Assoc J. 2000;2(9):712

686

Hartmann D, Güzelhan C, Zuiderwijk PBM, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol. 1996;50(5):421-424. doi: https://doi.org/10.1007/s002280050134

687

Madhava K, Hartley A. Hypothyroidism in Thyroid Carcinoma Follow-up: Orlistat May Inhibit the Absorption of Thyroxine [letter]. Clin Oncol. 2005;17(6):492. doi: https://doi.org/10.1016/j.clon.2005.05.001

688

Melia AT, Koss-Twardy SG, Zhi J. The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Absorption of Vitamins A and E in Healthy Volunteers. J Clin Pharmacol. 1996;36(7):647-653. doi: https://doi.org/10.1002/j.1552-4604.1996.tb04230.x

689

Zhi J, Melia AT, Koss-Twardy SG, et al. The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Pharmacokinetics of β-Carotene in Healthy Volunteers. J Clin Pharmacol. 1996;36(2):152-159. doi: https://doi.org/10.1002/j.1552-4604.1996.tb04180.x

690

Davidson MH, Hauptman J, DiGirolamo M, et al. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat. JAMA. 1999;281(3):235. doi: https://doi.org/10.1001/jama.281.3.235

691

Sjöström L, Rissanen A, Andersen T, et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention

692

Kushner RF. Clinical Assessment and Management of Adult Obesity. Circulation. 2012;126(24):2870-2877. doi: https://doi.org/10.1161/CIRCULATIONAHA.111.075424

693

Вахмистров А.В. Нарушения пищевого поведения при церебральном ожирении: Дис. … канд. мед. наук. — М.; 2001. [Vakhmistrov AV. Narusheniya pishchevogo povedeniya pri tserebral’nom ozhirenii. [dissertation] Moscow; 2001. (In Russ.)].

694

Dedov II. Ozhirenie. Moscow: MIA; 2004. 456 p. (In Russ.).

695

Mason TB, Lewis RJ. Profiles of Binge Eating: The Interaction of Depressive Symptoms, Eating Styles, and Body Mass Index. Eat Disord. 2014;22(5):450-460. doi: https://doi.org/10.1080/10640266.2014.931766

696

Pisetsky EM, Thornton LM, Lichtenstein P, et al. Suicide attempts in women with eating disorders. J Abnorm Psychol. 2013;122(4):1042-1056. doi: https://doi.org/10.1037/a0034902

697

Stunkard AJ, Costello Allison K. Two forms of disordered eating in obesity: binge eating and night eating. Int J Obes. 2003;27(1):1-12. doi: https://doi.org/10.1038/sj.ijo.0802186

698

Giannini J. The Eating Disorders ed. Slaby AE. editor. SpringerVerlag; New York Inc; 1993.

699

Malkina-Pykh IG. Terapiya pishchevogo povedeniya. Psikhologiya. Moscow: Eksmo; 2007. (In Russ.).

700

Smulevich A.B. Psikhicheskie rasstroistva v klinicheskoi praktike. Moscow: 2011. (In Russ.).

701

Dedov II, Mel’nichenko GA, Shestakova MV, et al. Natsional’nye klinicheskie rekomendatsii po lecheniyu morbidnogo ozhireniya u vzroslykh. 3-ii peresmotr (Lechenie morbidnogo ozhireniya u vzroslykh). Ozhirenie i metabolizm. 2018;15(1):53-70. (In Russ.). doi: https://doi.org/10.14341/OMET2018153-70

702

Lowe MR, Caputo GC. Binge eating in obesity: Toward the specification of predictors. Int J Eat Disord. 1991;10(1):49-55. doi: https://doi.org/10.1002/1098-108X(199101)10:1<49::AIDEAT2260100106>3.0.CO;2-X

703

Walsh BT. Eating Disorders: Progress and Problems. Science (80-). 1998;280(5368):1387-1390. doi: https://doi.org/10.1126/science.280.5368.1387

704

Cengiz Y, Karamustafalioglu O, Toker S. Prevalence of night eating syndrome and comorbidity with other psychiatric disorders in Psychiatric Outpatient Population. Yeni Symposium Journal. 2011;49(2):83-88.

705

Miján A. Eating disorders in obesity. Revista Espanola de Obesidad. 2006;4(6):317-327.

706

Brownley KA, Peat CM, La Via M, Bulik CM. Pharmacological Approaches to the Management of Binge Eating Disorder. Drugs. 2015;75(1):9-32. doi: https://doi.org/10.1007/s40265-014-0327-0

707

Schag K, Schönleber J, Teufel M, et al. Food-related impulsivity in obesity and Binge Eating Disorder — a systematic review. Obes Rev. 2013;14(6):477-495. doi: https://doi.org/10.1111/obr.12017

708

Wilfley DE, Friedman MA, Dounchis JZ, et al. Comorbid psychopathology in binge eating disorder: Relation to eating disorder severity at baseline and following treatment. J Consult Clin Psychol. 2000;68(4):641-649. doi: https://doi.org/10.1037/0022-006X.68.4.641

709

Cleator J, Abbott J, Judd P, Sutton C, Wilding JPH. Night eating syndrome: implications for severe obesity. Nutr Diabetes. 2012;2(9):e44-e44. doi: https://doi.org/10.1038/nutd.2012.16

710

Gerlach G, Herpertz S, Loeber S. Personality traits and obesity: a systematic review. Obes Rev. 2015;16(1):32-63. doi: https://doi.org/10.1111/obr.12235

711

Kessler RM, Hutson PH, Herman BK, Potenza MN. The neurobiological basis of binge-eating disorder. Neurosci Biobehav Rev. 2016;63(1):223-238. doi: https://doi.org/10.1016/j.neubiorev.2016.01.013

712

Voznesenskaya TG, Vakhmistrov AV. Kliniko-psikhologicheskii analiz narushenii pishchevogo povedeniya pri ozhirenii. Zhurn. nevrol. i psikhiatr. 2001;(12):19-24. (In Russ.).

713

Welch E, Jangmo A, Thornton LM, et al. Treatment-seeking patients with binge-eating disorder in the Swedish national registers: clinical course and psychiatric comorbidity. BMC Psychiatry. 2016;16(1):163. doi: https://doi.org/10.1186/s12888-016-0840-7

714

The Eating Disorders. Ed. by Giannini J, Andrew E. SpringerVerlag New York Inc.; 1993. 283 p.

715

Getmanchuk EI. Kliniko-psikhopatologicheskaya i mediko-psikhologicheskaya kharakteristika bol’nykh s psikhogennoi giperfagiei. Arkhіv psikhіatrії. 2012;3:(70):19-25. (In Russ.).

716

Palavras M, Hay P, Filho CAet al. The Efficacy of Psychological Therapies in Reducing Weight and Binge Eating in People with Bulimia Nervosa and Binge Eating Disorder Who Are Overweight or Obese — A Critical Synthesis and Meta-Analyses. Nutrients. 2017;9(3):299. doi: https://doi.org/10.3390/nu9030299

717

Melendez G, Serralde-Zúñiga AE, Gonzalez Garay AG, et al. Fluoxetine for adult overweight or obese people. Cochrane Database Syst Rev. May 2015. doi: https://doi.org/10.1002/14651858.CD011688

718

Ghaderi A, Odeberg J, Gustafsson S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6:e5113. doi: https://doi.org/10.7717/peerj.5113

719

Alfonsson S, Parling T, Ghaderi A. Group Behavioral Activation for Patients With Severe Obesity and Binge Eating Disorder. Behav Modif. 2015;39(2):270-294. doi: https://doi.org/10.1177/0145445514553093

720

Brownley KA, Berkman ND, Peat CM, et al. Binge-Eating Disorder in Adults. Ann Intern Med. 2016;165(6):409. doi: https://doi.org/10.7326/M15-2455

721

Peat CM, Berkman ND, Lohr KN, et al. Comparative Effectiveness of Treatments for Binge-Eating Disorder: Systematic Review and Network Meta-Analysis. Eur Eat Disord Rev. 2017;25(5):317-328. doi: https://doi.org/10.1002/erv.2517

722

Becker DF, Grilo CM. Comorbidity of mood and substance use disorders in patients with binge-eating disorder: Associations with personality disorder and eating disorder pathology. J Psychosom Res. 2015;79(2):159–64. doi: https://doi.org/10.1016/j.jpsychores.2015.01.016.

723

Fontenelle LF, Vltor Mendlowicz M, de Menezes GB, et al. Psychiatric comorbidity in a Brazilian sample of patients with binge-eating disorder. Psychiatry Res. 2003;119(1-2):189-94. doi: https://doi.org/10.1016/S0165-1781(03)00127-6.

724

Grilo C, White M, Barnes R, Masheb R. Psychiatric disorder co-morbidity and correlates in an ethnically diverse sample of obese patients with binge eating disorder in primary care settings. Comp Psychiatry. 2013;54:209-16. doi: https://doi.org/10.1016/j.comppsych.2012.07.012.

725

Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Comp Psychiatry. 2007;48(2):124–31. doi: https://doi.org/10.1016/j.comppsych.2006.08.002.

726

Hudson JI, Hiripi E, Pope HG, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348-58. doi: https://doi.org/10.1016/j.biopsych.2006.03.040.

727

Javaras KN, Pope HG, Lalonde JK, et al. Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry. 2008;69(2):266–73. doi: https://doi.org/10.4088/JCP.v69n0213.Y.

728

Bernstein BE, Bienenfeld D. Binge Eating Disorder (BED) Treatment & Management. Mar 30, 2020. Available from: https://emedicine.medscape.com/article/2221362-treatment.

729

Arnold LM, McElroy SL, Hudson JI, et al. A placebocontrolled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry. 2002;63:1028-33. doi: https://doi.org/10.4088/JCP.v63n1113

730

Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57:301-9. doi: https://doi.org/10.1016/j.biopsych.2004.11.002

731

Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the Treatment of Binge-Eating Disorder: A Multicenter PlaceboControlled, Double-Blind Trial. Am J Psychiatry. 1998;155(12):1756-1762. doi: https://doi.org/10.1176/ajp.155.12.1756

732

Guerdjikova AI, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 2008;23:1-11. doi: https://doi.org/10.1002/hup.899

733

McElroy SL, Casuto LS, Nelson EB, et al. Placebocontrolled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157:1004-6. doi: https://doi.org/10.1176/appi.ajp.157.6.1004

734

Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: A placebo-controlled trial. Int J Eat Disord. 2012;45(2):281-289. doi: https://doi.org/10.1002/eat.20946

735

Laederach-Hofmann K, Graf C, Horber F, et al. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: A randomized, placebo-controlled double-blind study. Int J Eat Disord. 1999;26(3):231-244. doi: https://doi.org/10.1002/(SICI)1098-108X(199911)26:3<231::AID-EAT1>3.0.CO;2-6

The authors declare that there are no conflicts of interest present.